Document:

Exhibit 4(b)

                                                             Executed in 6 Parts
                                                            Counterpart No. (  )

                              NATIONAL EQUITY TRUST

                        S&P 500 STRATEGY TRUST SERIES 21

                            REFERENCE TRUST AGREEMENT

      This  Reference  Trust  Agreement  dated October 1, 2003 among  Prudential
Investment Management Services LLC, as Depositor, Prudential Investments LLC, as
Portfolio  Supervisor,  and The Bank of New York, as Trustee, sets forth certain
provisions  in full  and  incorporates  other  provisions  by  reference  to the
document  entitled  "National Equity Trust,  Trust Indenture and Agreement" (the
"Basic  Agreement")  dated February 2, 2000. Such provisions as are set forth in
full herein and such provisions as are  incorporated  by reference  constitute a
single instrument (the "Indenture").

                                WITNESSETH THAT:

      In  consideration  of the  premises  and of the mutual  agreements  herein
contained, the Depositor and the Trustee agree as follows: Part I.

                     STANDARD TERMS AND CONDITIONS OF TRUST

      Subject to the provisions of Part II hereof, all the provisions  contained
in the Basic  Agreement are herein  incorporated  by reference in their entirety
and  shall be deemed  to be a part of this  instrument  as fully and to the same
extent as though said provisions had been set forth in full in this instrument.

A.    Article I, entitled "Definitions," shall be amended as follows:

(i)   Section  1.01-Definitions shall be amended to add the following definition
      at the end thereof:

<PAGE>

                                       -2-

      "Portfolio  Supervisor" of the Trust shall have the meaning assigned to it
in Part II of the Reference Trust Agreement.

B.    Article  III,  entitled  "Administration  of  Trust,"  shall be amended as
      follows:

      (i) The third paragraph of Section  3.05-Distribution  shall be amended by
deleting any reference to Depositor and replacing it with Portfolio Supervisor.

      (ii)  Section  3.14-Deferred  Sales  Charge  shall be  amended  to add the
following sentences at the end thereof:

"References to Deferred Sales Charge in this Trust Indenture and Agreement shall
include any Creation and  Development  Fee  indicated  in the  prospectus  for a
Trust.  The  Creation  and  Development  Fee  shall be  payable  on each date so
designated  and in an amount  determined  as specified in the  prospectus  for a
Trust."

C.    Article VIII, entitled "Depositor," shall be amended as follows:

      (i) Section  8.07-Compensation  shall be amended by deleting any reference
to Depositor and replacing it with Portfolio Supervisor.

D.    Article IX, entitled  "Additional  Covenants;  Miscellaneous  Provisions,"
      shall be amended as follows:

      (i) The first  sentence of Section 9.05 - Written  Notice shall be amended
by deleting  the language  "Prudential  Securities  Incorporated  at One Seaport
Plaza,  New York, New York 10292" and replacing it with  "Prudential  Investment
Management LLC at 100 Mulberry Street,  Gateway Center Three, Newark, New Jersey
07102".

                                    Part II.

                      SPECIAL TERMS AND CONDITIONS OF TRUST

        The following special terms and conditions are hereby agreed to:

<PAGE>

                                       -3-

A.    The Trust is  denominated  National  Equity Trust,  S&P 500 Strategy Trust
      Series 21.

B.    The Units of the Trust shall be subject to a deferred sales charge.

C.    The publicly  traded  stocks  listed in Schedule A hereto are those which,
      subject to the terms of this  Indenture,  have been or are to be deposited
      in Trust under this Indenture as of the date hereof.

D.    The term "Depositor" shall mean Prudential  Investment Management Services
      LLC.

E.    The term "Portfolio Supervisor" shall mean Prudential Investments LLC.

F.    The aggregate number of Units referred to in Sections 2.03 and 9.01 of the
      Basic Agreement is 125,000 as of the date hereof.

G.    A Unit of the Trust is hereby  declared  initially equal to 1/125,000th of
      the Trust.

H.    The term "First Settlement Date" shall mean October 7, 2003.

I.    The terms "Computation  Day" and  "Record  Date"  mean on the tenth day of
      December 2003, March 2004, June 2004, and September 2004.

J.    The  term  "Distribution  Date"  shall  mean  on  the  twenty-fifth day of
      December 2003, March 2004, June 2004, and September 2004.

K.    The term "Termination Date" shall mean January 5, 2005.

L.    The  Trustee's  Annual Fee shall be $.90 (per 1,000 Units) for  49,999,999
      and below Units  outstanding,  $.84 (per 1,000  Units) for  50,000,000  to
      99,999,999  Units  outstanding,  $.78 (per 1,000 Units) for 100,000,000 to
      199,999,999  Units  outstanding,  and $.66 (per 1,000  Units) for Units in
      excess of 200,000,000  Units. In calculating the Trustee's annual fee, the
      fee applicable to the number of units outstanding shall apply to all units
      outstanding.

M.    The Portfolio Supervisor's portfolio supervisory service fee shall be $.25
      per 1,000 Units.

               [Signatures and acknowledgments on separate pages]

<PAGE>

                                       -4-

The Schedule of Portfolio  Securities  in Part A of the  prospectus  included in
this  Registration  Statement for National Equity Trust,  S&P 500 Strategy Trust
Series 21 is hereby incorporated by reference herein as Schedule A hereto.

<PAGE>

                                            PRUDENTIAL INVESTMENT MANAGEMENT
                                            SERVICES LLC,
                                            (Depositor)

                                            By /s/ Richard R. Hoffmann
                                                   Richard R. Hoffmann
                                                   Vice President

                                            PRUDENTIAL INVESTMENTS LLC
                                            (Portfolio Supervisor)

                                            By /s/ Richard R. Hoffmann
                                                   Richard R. Hoffmann
                                                   Vice President

<PAGE>

                                                       THE BANK OF NEW YORK
                                                       Trustee

                                                   By: /s/ Brian Aarons
                                                           Brian Aarons
                                                           Title: Vice President

(SEAL)

ATTEST:

By:      /s/ Dorothy Alencastro
             Dorothy Alencastro
             Title: Assistant Vice President

STATE OF NEW YORK          )
                                            : ss.:
COUNTY OF NEW YORK         )

      I, Emanuel  Lytle,  Jr., a Notary Public in and for the said County in the
state  aforesaid,  do hereby  certify that Brian  Aarons and Dorothy  Alencastro
personally  known to me to be the same persons whose names are subscribed to the
foregoing  instrument  and  personally  known to me to be a Vice  President  and
Assistant Vice President,  respectively of The Bank of New York, appeared before
me this  day in  person,  and  acknowledged  that  they  signed,  sealed  with a
corporate  seal of The Bank of New York,  and delivered  the said  instrument as
their  free  and  voluntary  act as  such  Vice  President  and  Assistant  Vice
President,  respectively,  and as the free and  voluntary act of The Bank of New
York, for the uses and purposes therein set forth.

      GIVEN, under my hand and notarial seal this 1st day of October, 2003.

                                          /s/      Emanuel Lytle, Jr.
                                                   Emanuel Lytle, Jr.
                                                   Notary Public

(SEAL)<PAGE>

                                                                    EXHIBIT 10.4

                        DEVELOPMENT AND LICENSE AGREEMENT

                                     between

                          DISCOVERY THERAPEUTICS, INC.

                                       and

                            FUJISAWA HEALTHCARE, INC.

                        DEVELOPMENT AND LICENSE AGREEMENT

--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as *. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                              PAGE
                                                                              ----
<S>                                                                           <C>
1. DEFINITIONS ............................................................    2
   1.1  "A1 Agonist Library" ...............................................   2
   1.2  "Affiliate" ........................................................   2
   1.3  "Back-up Compound(s)" ..............................................   2
   1.4  "Back-up Compound Notice Period" ...................................   2
   1.5  "Compound" .........................................................   2
   1.6  "Data" .............................................................   2
   1.7  "Development Plan" .................................................   2
   1.8  "Diligent Efforts" .................................................   2
   1.9  "DTI Data" .........................................................   2
   1.10 "DTI Data Product" .................................................   2
   1.11 "DTI IND" ..........................................................   2
   1.12 "DTI Know-How" .....................................................   2
   1.13 "DTI Patents" ......................................................   3
   1.14 "DTI's Pre-clinical Studies" .......................................   3
   1.15 "DTI Target Dates" .................................................   3
   1.16 "Experimentation" ..................................................   3
   1.17 "FDA" ..............................................................   3
   1.18 "Field" ............................................................   3
   1.19 "FTE" ..............................................................   3
   1.20 "Fujisawa Data" ....................................................   3
   1.21 "Fujisawa Data Product" ............................................   3
   1.22 "Fujisawa Technology" ..............................................   3
   1.23 "IND" ..............................................................   4
   1.24 "Injectable Product" ...............................................   4
   1.25 "Injectable Protocol" ..............................................   4
   1.26 "Joint Management Committee" or "JMC" ..............................   4
   1.27 "Jointly Owned Patents" ............................................   4
   1.28 "Licensed Product(s)" ..............................................   4
   1.29 "NDA" ..............................................................   4
   1.30 "Net Sales" ........................................................   4
   1.31 "Non-Injectable Product" ...........................................   5
   1.32 "Non-Injectable Protocol" ..........................................   5
   1.33 "Phase I Trial" ....................................................   5
   1.34 "Phase II Trial" ...................................................   5
   1.35 "Phase III Trial" ..................................................   5
   1.36 "Primary Indications" ..............................................   5
   1.37 "PTO" ..............................................................   5
   1.38 "Regulatory Approval" ..............................................   5
   1.39 "Remaining Compounds" ..............................................   5
   1.40 "Territory" ........................................................   5
   1.41 "Third Party" ......................................................   5
</TABLE>

<PAGE>

<TABLE>
<S>                                                                            <C>
2. LICENSE GRANT ..........................................................    5
   2.1  License to Fujisawa ...............................................    5
   2.2  Sublicenses .......................................................    6
   2.3  Research License ..................................................    6
   2.4  Retained Rights ...................................................    6
   2.5  DTI Restrictive Covenant ..........................................    6
   2.6  Fujisawa Restrictive Covenant .....................................    6
   2.7  Disclosure of DTI Know-How ........................................    6
   2.8  Distribution Through Third Parties ................................    7
   2.9  Exclusivity .......................................................    7

3. PRODUCT DEVELOPMENT ....................................................    8
   3.1  General ...........................................................    8
   3.2  Engagement of Third Parties .......................................    8
   3.3  Joint Management Committee ........................................    8
   3.4  Development Plan ..................................................    8
   3.5  Diligence .........................................................    9
   3.6  Abandoned Products ................................................   10
   3.7  Clinical and Regulatory Matters ...................................   11
   3.8  Back-up Compounds .................................................   12
   3.9  Exchange of Information Between the Parties and Access to Data ....   13

4. COMMERCIALIZATION ......................................................   14
   4.1  General ...........................................................   14
   4.2  Failure to Launch .................................................   14
   4.3  Distribution and Promotion ........................................   15
   4.4  Trademarks ........................................................   15
   4.5  Exchange of Adverse Event Information .............................   15
   4.6  Regulatory Actions; Product Recalls; Product Withdrawals ..........   16

5. PAYMENTS AND ROYALTIES .................................................   17
   5.1  License Fees ......................................................   17
   5.2  Development Costs .................................................   17
   5.3  Milestones ........................................................   17
   5.4  Earned Royalties ..................................................   18
   5.5  Royalties to Fujisawa .............................................   18
   5.6  Additional Royalties to DTI .......................................   19
   5.7  Royalty Term ......................................................   19
   5.8  Withholding Taxes .................................................   20
   5.9  Blocked Currency ..................................................   20
   5.10 Royalty Payments and Reports ......................................   20
   5.11 Currency; Exchange Rate ...........................................   20
   5.12 Accounting ........................................................   21

6. MANUFACTURING ..........................................................   21
   6.1  General ...........................................................   21
   6.2  Quality Assurance .................................................   21
</TABLE>

                                       ii

<PAGE>

<TABLE>
<S>                                                                           <C>
7.  REPRESENTATIONS AND WARRANTIES; DISCLAIMERS ...........................   22
    7.1 Representations and Warranties ....................................   22
    7.2 Warranty Disclaimer ...............................................   23

8.  INDEMNITY AND INSURANCE ...............................................   23
    8.1 Indemnification by Fujisawa .......................................   23
    8.2 Indemnification by DTI ............................................   24
    8.3 Indemnification Procedure .........................................   24
    8.4 Insurance .........................................................   24

9.  PROTECTION OF PATENTS; CLAIMS OF INFRINGEMENT .........................   24
    9.1 Ownership of Intellectual Property ................................   24
    9.2 Infringement of DTI Patents .......................................   25
    9.3 Defense and Settlement of Third Party Claims of Patent
        Infringement.......................................................   26
    9.4 Prosecution and Maintenance of DTI Patents ........................   26
    9.5 Prosecution and Maintenance of Joint Patents ......................   27

10. CONFIDENTIALITY .......................................................   27
    10.1 Information ......................................................   27
    10.2 Exceptions .......................................................   27
    10.3 Permitted Disclosures ............................................   28
    10.4 Disclosure of Agreement; Press Releases ..........................   28

11. TERM AND TERMINATION ..................................................   28
    11.1 Term .............................................................   28
    11.2 Early Termination for Material Breach ............................   29
    11.3 Termination for Bankruptcy .......................................   29
    11.4 Early Termination by Fujisawa ....................................   29
    11.5 Termination of Entire Agreement ..................................   30
    11.6 Effect of Partial Termination ....................................   30
    11.7 Effect of Early Termination ......................................   31
    11.8 Accrued Obligations ..............................................   33
    11.9 Surviving Obligations ............................................   33

12. ASSIGNMENT ............................................................   33

13. DISPUTE RESOLUTION ....................................................   33
    13.1 Discussion .......................................................   33
    13.2 Alternative Dispute Resolution ...................................   34
    13.3 Mediation ........................................................   34
    13.4 Arbitration ......................................................   35
    13.5 Procedure ........................................................   35

14. GENERAL ...............................................................   36
    14.1 Notices ..........................................................   36
    14.2 Retained Rights ..................................................   37
    14.3 Consents Not Unreasonably Withheld or Delayed ....................   37
    14.4 Force Majeure ....................................................   37
</TABLE>

                                       iii

<PAGE>

<TABLE>
<S>                                                                           <C>
    14.5   Further Actions ................................................   37
    14.6   No Trademark Rights ............................................   37
    14.7   Waiver .........................................................   37
    14.8   Independent Contractors ........................................   38
    14.9   Entire Agreement ...............................................   38
    14.10  Governing Law ..................................................   38
    14.11  Severability ...................................................   38
    14.12  Counterparts ...................................................   38
</TABLE>

                                       iv

<PAGE>

                        DEVELOPMENT AND LICENSE AGREEMENT

                                     between

                          DISCOVERY THERAPEUTICS, INC.

                                       and

                            FUJISAWA HEALTHCARE, INC.

                        DEVELOPMENT AND LICENSE AGREEMENT

         THIS DEVELOPMENT AND LICENSE AGREEMENT (the "Agreement"), dated as of
July 29, 1999 (the "Effective Date"), is made by DISCOVERY THERAPEUTICS, INC., a
Delaware corporation having a principal place of business at 2028 Dabney Road,
Suite E-17, Richmond, VA 23230-3311, U.S.A. ("DTI"), and FUJISAWA HEALTHCARE,
INC., a Delaware corporation having a principal place of business at Parkway
North Center, Three Parkway North, Deerfield, Ill. 60015 ("Fujisawa"). DTI and
Fujisawa are sometimes referred to herein individually as a "Party" and
collectively as the "Parties."

                                   WITNESSETH

         WHEREAS, DTI owns certain patents, patent applications and know-how
relating to DTI's proprietary adenosine receptor agonist DTI 0009 and various
other compounds;

         WHEREAS, DTI has successfully advanced DTI 0009 through preclinical
development and is about to or has commenced Phase I clinical trials;

         WHEREAS, Fujisawa is a health care company with development and
marketing activities in North America, and which desires to obtain additional
potential drug products to sell in the United States and Canada for the
treatment, through an injectable mode of administration, of paroxysomal
supraventricular tachycardias ("PSVT") and atrial fibrillation and flutter
("AFIB/F") in humans, among other potential indications; and

         WHEREAS, DTI wishes to license the rights, upon the terms and
conditions contained in this Agreement, to Fujisawa in the United States and
Canada to develop and commercialize pharmaceutical products containing DTI 0009
or Back-up Compounds (as hereinafter defined) for the treatment, through an
injectable mode of administration, of all diseases in humans, including but not
limited to PSVT and AFIB/F.

         NOW, THEREFORE, in consideration of the above premises and covenants
contained herein, the Parties agree as follows:

<PAGE>

1.       DEFINITIONS

         1.1      "A1 Agonist Library" means all of the Al agonist compounds
that are owned, licensed to or controlled by DTI and that are covered by one or
more claims within the DTI Patents.

         1.2      "Affiliate" means any entity that directly or indirectly Owns,
is Owned by or is under common Ownership with, a Party to this Agreement.
"Owns," "Owned" or "Ownership" means direct or indirect possession of at least
fifty percent (50%) of the outstanding voting securities of a corporation or a
comparable equity interest in any other type of entity.

         1.3      "Back-up Compound(s)" means any compound that Fujisawa selects
from the A1 Agonist Library pursuant to Section 3.8, for use as provided in
Section 3.8(b).

         1.4      "Back-up Compound Notice Period" shall have the meaning
ascribed to it in Section 3.8(a)(i).

         1.5      "Compound" means the compound known as DTI 0009, which is
further described in Exhibit A attached hereto.

         1.6      "Data" shall mean any and all data, reports, and/or
documentation (or analyses thereof) generated in connection with clinical
trials, preclinical studies or other investigations of the Compound or any
Back-up Compound.

         1.7      "Development Plan" means the development plan, as may be
amended, that is described in Section 3.4.

         1.8      "Diligent Efforts" means the carrying out of obligations in a
sustained manner consistent with the efforts a Party devotes to a product of
similar market potential, profit potential or strategic value resulting from its
own research efforts, based on conditions then prevailing. Diligent Efforts
requires, at a minimum, that: (i) the Party promptly assigns responsibility for
such obligations to specific employee(s) who are held accountable for progress
and monitor such progress on an on-going basis, (ii) the Party sets and
consistently seeks to achieve specific and meaningful objectives for carrying
out such obligations, and (iii) the Party consistently makes and implements
decisions and allocates resources designed to advance progress with respect to
such objectives.

         1.9      "DTI Data" shall have the meaning ascribed to it in Section
3.9.

         1.10     "DTI Data Product" shall have the meaning ascribed to it in
Section 5.6.

         1.11     "DTI IND" shall have the meaning ascribed to it in Section
2.7(b).

         1.12     "DTI Know-How" means any and all pre-clinical, clinical,
technical, scientific, medical, sales and marketing information, data,
knowledge, methods, inventions, materials, practices and trade secrets
including, but without limitation, manufacturing processes and techniques,
quality control information and procedures and pharmacological, toxicological
and

                                       2

<PAGE>

clinical test data and results, which is (i) owned by, controlled by, or
licensed to DTI as of the Effective Date or is invented or developed by or
licensed to DTI during the term of this Agreement (and available for sublicense
to or otherwise able to be disclosed to Fujisawa), and (ii) necessary for,
useful for or used in the manufacture, use, development, registration,
formulation, sale, or marketing of a Licensed Product in the Field. DTI Know-How
shall exclude the DTI Data, but shall include all Data generated by DTI in the
conduct of the Phase I Trial and DTI's Pre-Clinical Studies.

         1.13     "DTI Patents" means any and all patents, patent applications
or patents issuing from such applications, and all reissues, reexaminations,
continuations, continuations-in-part, divisionals, extensions, or Supplemental
Protection Certificates, which cover the manufacture, use, sale, offer for sale,
importation or exportation of the Compound or Licensed Product in the Territory,
which are owned by, controlled by or licensed to DTI either directly or
indirectly, including specifically, but without limitation, U.S. Patent No.
5,310,731, and including any Jointly Owned Patents. The DTI Patents are set
forth on Exhibit F, which shall be amended from time to time to include DTI
Patents issued or filed from and after the Effective Date.

         1.14     "DTI's Pre-clinical Studies" shall have the meaning ascribed
thereto in Section 7.1(x).

         1.15     "DTI Target Dates" shall have the meaning ascribed to it in
Section 3.4.

         1.16     "Experimentation" shall mean the conduct of scientific
experiments with respect to a compound in the Al Agonist Library, as evidenced
by laboratory notebook entries regarding such experiments.

         1.17     "FDA" means the United States Food and Drug Administration or
its equivalent in Canada, or any successor entity thereto.

         1.18     "Field" means the diagnosis, prevention and/or treatment of
diseases, syndromes or conditions in humans, including but not limited to PSVT
and AFIB/F.

         1.19     "FTE" is an acronym that stands for Full Time Equivalent,
which shall mean one or more researchers employed by DTI and possessing skills
and experience necessary to carry out applicable tasks described in Section
2.7(a) with such time and effort to constitute one such researcher working the
equivalent of a full year of effort on a full time basis (not less than 40 hours
per week).

         1.20     "Fujisawa Data" shall have the meaning ascribed to it in
Section 3.9.

         1.21     "Fujisawa Data Product" shall have the meaning ascribed to it
in Section 5.5.

         1.22     "Fujisawa Technology" means, to the extent necessary or useful
to make, use or sell a Licensed Product, all patents and patent applications and
information, trade secrets, data, inventions and know-how, owned by, controlled
by, or licensed to Fujisawa (with the right to sublicense) provided that
Fujisawa Technology shall only include such patents, patent applications,
information, trade secrets, data (including the Fujisawa Data), inventions and

                                       3

<PAGE>

know-how as were developed or owned by or licensed to Fujisawa: (a) from and
after the date of this Agreement; and (b) solely in connection with the Compound
and Back Up Compound. Fujisawa Technology shall not include the DTI Patents, DTI
Know-How and any and all patents, patent applications, information, trade
secrets, data, inventions and/or know how developed, owned or licensed by
Fujisawa in connection with and/or relative to Fujisawa's license arrangements
with Medco Research, Inc. Fujisawa Technology shall not include trademarks for
any Licensed Products, which shall be handled in accordance with Section 4.4.

         1.23     "IND" means an investigational new drug application, as
defined by the FDA in 21 CFR Part 312, or the equivalent application in Canada.

         1.24     "Injectable Product" means a product that is formulated solely
for intravenous, subcutaneous, intracoronary, intraarterial or intramuscular
administration.

         1.25     "Injectable Protocol" shall have the meaning ascribed to it in
Section 2.7(b).

         1.26     "Joint Management Committee" or "JMC" means the Committee
described in Section 3.3.

         1.27     "Jointly Owned Patents" shall be defined as set forth in
Section 9.5.

         1.28     "Licensed Product(s)" means an Injectable Product that
contains as its active ingredient the Compound or a Back-up Compound.

         1.29     "NDA" means a New Drug Application as defined by the FDA in 21
C.F.R. Part 314, or its equivalent in Canada.

         1.30     "Net Sales" means gross amounts invoiced for the sale of the
Licensed Product(s) in finished package form sold by Fujisawa or its
sublicensees, less

                  (a) any and all normal and customary trade and quantity
discounts, customary allowances actually granted to purchasers of the Licensed
Product(s) for returns and recalled Licensed Product (whether in the form of
either a credit or free replacements actually given in place of returned or
recalled Licensed Product(s), allowances to end users (whether in the form of
either a credit or free product) participating in Fujisawa Sponsored Trial
Support, capitation, market share or stop loss agreements, or other compliance
incentive programs, Medicaid rebates given pursuant to agreement with U.S.
Department of Health and Human Services and any other rebates given pursuant to
government based rebate programs (including without limitation state and local
rebate programs) whether currently in effect or which become effective during
the term of this Agreement, administrative fees to managed health care
organizations (including but not limited to Group Purchasing Organizations,
HMO's etc.), chargeback and reporting rebates paid to wholesalers and other
distributors;

                  (b) freight expenses for shipping finished product to such
purchasers; and

                  (c) excise and value added taxes applicable to sales of the
Licensed Products) in finished package form which Fujisawa has to pay or absorb
on such sales.

                                       4

<PAGE>

No deductions shall be made for commissions paid to individuals whether they be
with independent sales agencies or regularly employed by Fujisawa, and/or its
sublicensee(s) and on its or their payroll, or for cost of collections. Licensed
Products shall be considered "sold" when billed out or invoiced. Sale or
transfer to an Affiliate or sublicensee for re-sale by such Affiliate or
sublicensee shall not be considered a sale for the purpose of this provision,
but the resale by such Affiliate or sublicensee to a Third Party shall be a sale
for such purposes.

         1.31     "Non-Injectable Product" means any product which is (i) not an
Injectable Product, including, without limitation, those formulated for
administration through the alimentary canal, including by mouth or for use in
the mouth through sublingual absorption and/or absorption through submucosal or
buccal tissue, and through transdermal administration, including absorption
through rectal tissue and (ii) which contains as its active ingredient a
Compound or a Back-up Compound.

         1.32     "Non-Injectable Protocol" shall have the meaning ascribed to
it in Section 2.7(b).

         1.33     "Phase I Trial" means the Phase I clinical trial to be
performed by DTI pursuant to the Protocol Number DTI 0009-001.

         1.34     "Phase II Trial" means the first dose finding trial in
patients.

         1.35     "Phase III Trial" means the first controlled clinical trial
after dose finding trials.

         1.36     "Primary Indications" means PSVT and AFIB/F.

         1.37     "PTO" means the United States Patent and Trademark Office.

         1.38     "Regulatory Approval" means all approvals by the applicable
regulatory agency in the relevant country of the Territory necessary to market
and sell a Licensed Product.

         1.39     "Remaining Compounds" shall have the meaning ascribed to it in
Section 3.8(a)(ii).

         1.40     "Territory" means the United States and its territories and
possessions, and Canada.

         1.41     "Third Party" means any entity other than DTI or Fujisawa.

2.       LICENSE GRANT

         2.1      License to Fujisawa. Subject to the terms of Article 2 and the
other terms and conditions of this Agreement, and except as provided in Section
3.8(a)(iii), DTI hereby grants and Fujisawa hereby accepts an exclusive (even as
to DTI) license, with the right to sublicense as provided in Section 2.2, under
the DTI Patents and DTI Know-How to make, have made, use, sell, offer to sell,
have sold, export and import Licensed Products in the Field and in the
Territory. It is expressly understood by Fujisawa that the exclusivity grant in
this Section 2.1 is

                                       5

<PAGE>

subject to the provisions of Section 3.8(a)(iii), which may have the effect of
reducing the exclusivity in the Field for Licensed Products containing certain
Back-up Compounds from all indications to only the Primary Indications.

         2.2      Sublicenses. Fujisawa shall have the right to grant
sublicenses at any time to a Third Party with respect to any rights conferred
upon Fujisawa under this Agreement; provided, however, that (i) any such
sublicense shall be subject in all respects to the restrictions, royalty and
other payment obligations, reports, and other provisions contained in this
Agreement, including but not limited to the obligations set forth in Article 3,
(ii) Fujisawa shall notify DTI of the identity of such sublicensee promptly on
execution of the sublicense; and (iii) subject to any confidentiality
restrictions set forth in such sublicense agreements, Fujisawa shall forward to
DTI a copy of any and all sublicense agreements promptly upon execution by the
parties thereto.

         2.3      Research License. Subject to the conditions and limitations
set forth in this Agreement, Fujisawa hereby grants to DTI an exclusive (except
as to Fujisawa), paid-up license, under the Fujisawa Technology to conduct
research and development activities for the Phase I Trial with respect to
Licensed Products pursuant to the Development Plan.

         2.4      Retained Rights. Subject to Section 2.5, DTI retains any and
all rights under the DTI Patents and DTI Know-How not expressly licensed to
Fujisawa under this Agreement, specifically including, but without limitation,
any and all rights to make, have made, use, sell, have sold, export or import
(i) compounds covered by one or more claims in the DTI Patents other than the
Compound and any Back-up Compound selected pursuant to Section 3.8 for any use,
(ii) any Non-Injectable Products and (iii) Licensed Products outside of the
Territory.

         2.5      DTI Restrictive Covenant. DTI covenants that during the term
of this Agreement it shall not, license (in whole or in part), conduct, fund,
develop or participate in, directly or indirectly through one or more Third
Parties, the research, development, distribution or commercialization in the
Territory of any Injectable Products to treat the Primary Indications. DTI
further covenants that it shall not, during the term of this Agreement, license
(in whole or in part), conduct, fund, develop or participate in, directly or
indirectly through one or more Third Parties, the research, development,
distribution or commercialization in the Territory of any Licensed Products in
the Field, subject to the terms of Section 3.8(a)(iii) and the last sentence of
Section 2.1 DTI shall be further restricted in its development and
commercialization efforts as set forth in Section 3.8(a)(i). The provisions of
this Section 2.5 shall not apply to the extent that DTI obtains from Fujisawa
the right to develop and commercialize a Licensed Product in the Field in the
Territory, whether pursuant to Section 3.5(b), 3.6, 4.2(a), or Article 11.

         2.6      Fujisawa Restrictive Covenant. Fujisawa covenants that it
shall not use or practice the DTI Patents or DTI Know-How to make, offer to
sell, have made, use, sell, have sold, export or import Licensed Products in the
United States for any uses except as expressly granted in Section 2.1.

         2.7      Disclosure of DTI Know-How.

                  (a)      Upon signing the Agreement, and subject to the
obligations of confidentiality set forth in this Agreement, DTI shall disclose
to Fujisawa and provide copies of

                                       6

<PAGE>

all documentation of DTI Know-How, including, but not limited to, all of DTI's
data regarding its Al Agonist Library and the DTI IND. Except as provided in
Section 3.8(a)(iv), DTI shall also promptly provide to Fujisawa a copy of any
additional or new documents covering the DTI Know-How that may come into DTI's
possession after the Effective Date, including, in (a) particular any Data
generated in connection with the Phase I Trial. In addition, DTI shall make
available to Fujisawa, upon reasonable notice and during normal business hours,
the reasonable assistance of DTI's employees who are knowledgeable about the DTI
Know-How and DTI Patents in order to facilitate Fujisawa's efforts to develop
and commercialize Licensed Products. DTI shall provide the assistance of at
least one (1) FTE for a period of 1 year from the Effective Date, and thereafter
at and for such times as Fujisawa may request. Fujisawa may, at its option,
request that DTI provide and DTI shall provide, upon such request, such
additional FTEs. Fujisawa shall reimburse DTI for such assistance at a rate
equivalent to * annually per FTE, payable in equal quarterly installments
commencing ninety (90) days from the Effective Date, but may terminate its right
to receive DTI's assistance at any time after the first anniversary of the
Effective Date.

                  (b)      The Parties acknowledge and agree that an IND was
submitted by DTI to the FDA on July 12, 1999 covering both the Licensed Product
and the Non-Injectable Product (the "DTI IND"). The Protocol Number for the
Phase I Trial for the Licensed Product is DTI-0009-001 ("Injectable Protocol")
and the Protocol Number for the Phase I Trial for the Non-Injectable Product is
DTI-0009-002 ("Non-Injectable Protocol"). DTI will, at Fujisawa's expense,
transfer to Fujisawa the DTI IND together with any and all regulatory files,
reports, data, written information and related documentation associated with
such submission and promptly notify FDA in writing of such transfer. DTI will
make such transfer within thirty (30) days after the date DTI completes the
Phase I Injectable Protocol for the Licensed Product or within 30 days after the
date Fujisawa exercises its option under Section 3.5(a)(ii), whatever date is
earlier; provided however, that if transfer is delayed due to actions, lack of
action, or policies of FDA, then the period for transfer shall be extended by
the length of the relevant delay. The Parties acknowledge and agree that if such
transfer is delayed due to the actions, lack of action or policies of the FDA or
DTI, then the "Critical Target Dates" (as hereinafter defined) or other
obligations due from Fujisawa shall be extended by the length of the relevant
delay. The Parties further acknowledge and agree that once the DTI IND is
transferred to Fujisawa: (i) Fujisawa will notify the FDA that the DTI IND does
not cover the Non-Injectable Product and/or the Non-Injectable Protocol; (ii)
except as otherwise provided in this Agreement, Fujisawa will have no
responsibility whatsoever with respect to the Non-Injectable Protocol; (iii) at
the same time as such transfer, DTI shall submit its own IND for the
Non-Injectable Protocol; and (iv) the Parties shall be entitled to cross
reference the IND of the other party, once DTI's IND for the Non-Injectable
Product, has been allowed by the FDA.

         2.8      Distribution Through Third Parties. DTI grants Fujisawa the
right to distribute Licensed Products through Third Party distributors in the
Territory; provided, that Fujisawa shall use distributors with expertise and
distribution capacity appropriate to the Licensed Product.

         2.9      Exclusivity. For the purposes of this Article 2, the phrase
"exclusive except as to" shall mean that the licensee and the licensor shall
share the rights granted in the relevant license grant, and the phrase
"exclusive even as to" shall mean that the grantor shall retain none

-------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
-------------------------------------------------------------------------------

                                       7

<PAGE>

of the rights granted in the relevant license grant. Rights that are sublicensed
pursuant to this Article 2 shall be exclusive only to the extent the licensor
holds exclusive rights.

3.       PRODUCT DEVELOPMENT

         3.1      General. DTI shall be responsible for conducting the Phase I
Trial for the Compound for the Primary Indications. Fujisawa shall be
responsible for all other aspects pertaining to the development of, and
obtaining Regulatory Approval for, the Licensed Products in the Territory.
Subject to Section 3.5(c), Fujisawa shall have the final decision-making
authority with respect to all aspects of the development of the Licensed
Products.

         3.2      Engagement of Third Parties. In the course of performing its
development obligations under this Agreement, either Party may engage Third
Parties to perform certain development activities, provided that (i) the other
Party is informed of the use and identity of Third Parties for the relevant
activity, and (ii) each Party obtains contractual undertakings from such Third
Parties (including in particular with respect to quality assurance, compliance
with law, and confidentiality) as may be applicable to, and customary in the
pharmaceutical industry for, the relevant activity to be performed by such Third
Party.

         3.3      Joint Management Committee. Promptly after the Effective Date,
the Parties shall form a Joint Management Committee ("JMC") which shall consist
of two (2) representatives of each Party with expertise in such disciplines as
clinical, regulatory affairs, manufacturing or marketing. One of the Fujisawa
representatives shall serve as the chairperson of the JMC. All decisions of the
JMC shall be made by a majority vote of the representatives on the JMC;
provided, that Fujisawa shall cast the decisive tie-breaking vote in the event
that the JMC is unable to come to a decision on any matter, subject to Section
3.5(c). Either Party may bring additional non-voting representatives to the
meetings of the JMC so long as such Party provides prior notice at the time
Fujisawa is required to provide an agenda under this Section 3.3 to the other
Party that it intends to bring such representatives. The JMC shall meet
regularly (but in no event less than three times per year) at such times and at
such locations as shall be mutually agreed by the Parties. The JMC shall review
development activities of DTI and Fujisawa in accordance with the Development
Plan including, but not limited to, the choice of contract research
organization, consultants, Third Party contract manufacturers and assignment of
development activities, the development of new formulations and other product
changes, and communication with FDA and other Third Parties. At least 10
business days prior to each regularly scheduled meeting of the JMC, Fujisawa and
DTI shall provide a written status report to the JMC concerning its progress
with respect to the Development Plan and Fujisawa shall provide an agenda for
the upcoming meeting. Promptly after each meeting of the JMC, the chairperson
shall provide minutes of such meeting.

         3.4      Development Plan. Attached to this Agreement as Exhibit B is a
Development Plan setting forth (i) DTI's anticipated timeline for commencement
and completion of the Phase I Trial (the "DTI Target Dates"); and (ii)
Fujisawa's anticipated timeline for the development program for the Licensed
Product for the treatment of the Primary Indications in the United States,
including target dates for key clinical and regulatory events ("Critical Target
Dates"). The Critical Target Dates shall include, without limitation, the date
by which Fujisawa shall

                                       8

<PAGE>

enroll the first patient in Phase II and III clinical trials for the Licensed
Product for the treatment of the Primary Indications (the "Clinical Target
Dates"), and the date of submission of applications for Regulatory Approval in
the United States. Fujis awa anticipates the commercial launch date for each
Licensed Product to be *from the date of Regulatory Approval for each such
Licensed Product. The Development Plan may be amended from time to time in
writing by the JMC, subject to Section 3.5(c). Any amended Development Plan
shall be attached hereto at Exhibit B.

         3.5      Diligence.

                  (a)      Development Efforts.

                           (i)      Fujisawa shall use Diligent Efforts to carry
out development of the Licensed Product for the treatment of the Primary
Indications in accordance with the Development Plan. If Fujisawa determines that
it will be unable to meet any of the Critical Target Dates identified in the
Development Plan within six (6) months after the date specified in such
Development Plan, it shall notify the JMC within thirty (30) days of such
determination. The JMC shall develop a revised Development Plan for the Licensed
Product which shall include new Critical Target Dates, provided however, that
DTI's JMC representatives must agree to the new Critical Target Dates. In the
event DTI's voting representatives do not agree to the Critical Target Dates set
forth in the revised Development Plan, then either Party may, at its election,
proceed under Section 3.5(c).

                           (ii)     DTI shall use Diligent Efforts to carry out
the Phase I Trial in accordance with the Development Plan. If DTI fails to, or
expects that it will fail to, meet any DTI Target Date, by more than three (3)
months, Fujisawa may, at its option, assume control of and complete the Phase I
Trial. In such event, the Parties shall cooperate fully and take all necessary
steps to obtain the necessary Regulatory Approvals to effectuate the transfer of
the Phase I Trial.

                  (b)      Extended Delay. Subject to Section 11.5, if Fujisawa
(i) fails to meet any of the Clinical Target Dates then in effect for the
Licensed Product for a given Primary Indication within 12 months after the
relevant Clinical Target Date specified in the Development Plan for such Primary
Indication, or (ii) fails to submit for Regulatory Approval of that Licensed
Product for such Primary Indication in the United States within 18 months after
the date specified for such submission in the Development Plan with respect to
such Licensed Product, then DTI may terminate Fujisawa's rights under this
Agreement with respect to such Licensed Product for such particular Primary
Indication. In such event, Fujisawa shall promptly transfer to DTI all INDs or
their Canadian equivalent and other relevant regulatory filings as it may hold
with respect to that Licensed Product for the particular Primary Indication, and
any information as Fujisawa may possess which is necessary or useful to gain
Regulatory Approval for and to commercialize such Licensed Product in the
Territory for such Primary Indication. Such transfer shall be without cost to
DTI, provided however that DTI shall pay any governmental filing or transfer
fees that may be required. Fujisawa also grants to DTI, effective only in the
event its rights to such Licensed Product for such Primary Indication are
terminated under this Section 3.5(b), an exclusive fully paid and royalty-free
(subject to DTI's obligations under Section 5.5)

-------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
-------------------------------------------------------------------------------

                                       9

<PAGE>

license under the Fujisawa Technology to make, have made, use, import, export,
offer for sale and sell such Licensed Product for such Primary Indication and,
to the extent it has the right to do so, grant to DTI a sublicense under any
Third Party licenses to which Fujisawa has rights, to the extent that such
rights are necessary or useful to make, have made, use, import, export, offer
for sale and sell the Licensed Product. DTI shall thereafter assume the cost of
maintaining its proportionate share of such Third Party license and shall
perform such obligations of Fujisawa under such license agreement as are
applicable to the relevant Licensed Product. To the extent such Third Party
license is no longer applicable or useful to Fujisawa, Fujisawa shall assign to
DTI all of its rights and obligations thereunder, rather than grant a sublicense
under, such license agreement. The JAM shall have no authority with respect to
the development and commercialization of a Licensed Product as to which rights
have reverted to DTI under this Section 3.5(b).

                  (c)      Disputes Regarding Critical Target Dates. If the
Parties are unable to reach agreement as to the Critical Target Dates in any
proposed revision to the Development Plan, then either Party may submit the
issue for binding arbitration pursuant to Section 13.4, provided that such
arbitration shall be conducted before an expert or expert panel in the field of
clinical drug development (rather than before a judge or an attorney). Such
expert may be mutually agreed upon by the Parties, but if no such expert is
agreed upon within ten (10) days after the written notice from one Party to the
other, then each Party shall promptly select one expert, and those two experts
shall select a third expert, which shall comprise the panel. Notwithstanding any
provisions concerning duration of arbitration proceedings set forth in Section
13.4, the panel shall meet with the Parties within thirty (30) days of selection
to examine such proposed revisions to the Development Plan and shall hear the
views and proposals of each Party. Within ten (10) days thereafter, it shall
render its binding decision by majority vote, as to whether the Critical Target
Dates proposed in the revised Development Plan are reasonable under all of the
circumstances. The Parties shall share equally in the cost of the expert or
expert panel, including any fees and expenses payable to the experts. If the
expert or expert panel determines that the proposed Critical Target Dates are
not reasonable, then Fujisawa will be held to the Critical Target Dates set
forth in the most recently approved Development Plan, subject to any
modifications agreed to by DTI. If such Critical Target Dates have passed as of
the date of the expert's or expert panel's decision, the panel shall set new
Critical Target Dates, taking into consideration the views and proposals
presented by the Parties in the course of the proceedings conducted under this
Section 3.5(c).

         3.6      Abandoned Products. Subject to Section 11.5, if Fujisawa
decides, at any time or from time to time, that it does not desire to commence
or continue research, development or commercialization activities, including
without limitation, conducting clinical development or seeking Regulatory
Approval of a Licensed Product (for either of the Primary Indications or any
other indications) or to sublicense any of the foregoing activities, it shall
provide written notice to DTI within thirty (30) days of such decision. Upon
receipt of such notice, DTI may, at its election, terminate Fujisawa's rights
under this Agreement with respect to such Licensed Product for such indication.
In such event, Fujisawa shall (i) promptly transfer to DTI all INDs and their
Canadian equivalent (as applicable) and other relevant regulatory filings as it
may hold with respect to such Licensed Product for such indication, and any and
all written information as Fujisawa may possess which is useful to gain
Regulatory Approval for and to commercialize

                                       10

<PAGE>

such Licensed Product for such indication. Such transfer shall be without cost
to DTI, provided however that DTI shall pay any governmental filing or transfer
fees that may be required; (ii) grant to DTI an exclusive fully paid and
royalty-free license under the Fujisawa Technology to make, have made, use,
import, offer for sale and sell (subject to DTI's obligations under Section 5.5)
such Licensed Product for such indication in the Territory, and (iii) to the
extent it has the right to do so, grant to DTI a sublicense under any Third
Party licenses to which Fujisawa has rights, to the extent that such rights are
necessary or useful to make, have made, use, import, offer for sale and sell
such Licensed Product for such indication in the Territory. DTI shall thereafter
assume the cost of maintaining its proportionate share of such Third Party
license and shall perform such obligations of Fujisawa under such license
agreement as are applicable to the relevant Licensed Product. To the extent such
Third Party license is no longer applicable or useful to Fujisawa, Fujisawa
shall assign to DTI all of its rights and obligations thereunder, rather than
grant a sublicense under, such license agreement. The JMC shall have no
authority with respect to the development and commercialization of a Licensed
Product as to which rights have reverted to DTI under this Section 3.6.

         3.7      Clinical and Regulatory Matters.

                  (a)      Clinical Trials. DTI shall be responsible for
conducting the Phase I Trial for the Compound for the Primary Indications under
the Injectable Protocol. Fujisawa shall be responsible for conducting, at its
expense, all other non-clinical and clinical studies necessary to obtain
Regulatory Approval of the Licensed Products in the Territory in accordance with
the Development Plan. The Parties shall conduct all such clinical trials in
accordance with the applicable laws and regulations of the country in which the
data generated in such clinical trial will be used to support an application for
Regulatory Approval of the relevant Licensed Product.

                  (b)      Drug Approval Applications Fujisawa shall be
responsible for preparing and submitting, at its expense, applications for
Regulatory Approval of the Licensed Products in the Territory. Fujisawa will
submit the drug approval applications in its own name and shall be responsible
for obtaining Regulatory Approval in the Territory and shall use Diligent
Efforts to pursue and obtain Regulatory Approval in the U.S.

                  (c)      Reporting. The Parties shall keep each other
reasonably informed as to the progress of the clinical trials for which each is
responsible and drug approval applications and of any issues raised by the
relevant regulatory agencies together with Fujisawa' proposed response. The
Parties shall provide each other with such reports on a periodic basis but not
less than every four (4) months at the regular meetings of the JMC. Each Party
shall report to the other concerning its progress with respect to clinical
trials and applications for Regulatory Approval, including providing the other
with written notice as soon as it has completed enrollment and dosed the last
patient in each Phase I, II and III clinical trial.

                  (d)      Responsibility. Subject to each Party's right to
cross reference the other's Data and regulatory filings under Section 3.9, any
and all regulatory applications and approvals in the Territory, including
without limitation the IND and NDA for each Licensed Product shall be held
solely by Fujisawa; provided, however, DTI shall hold the DTI IND until such
time as it completes the Phase I Trial, at which point it will transfer the DTI
IND to Fujisawa as provided

                                       11

<PAGE>

in Section 2.7 or 3.5(a)(ii). DTI shall be responsible for all regulatory
matters associated with the DTI IND during such time as it is the holder of the
DTI IND as provided above; provided, that Fujisawa shall be included in all
meetings and/or discussions with the FDA. DTI shall give Fujisawa at least 48
hours advance notice prior to any such meeting or discussion. DTI shall provide
Fujisawa within 72 hours after any such meeting or discussion any documentation
or correspondence from or with the FDA. After DTI transfers the DTI IND to
Fujisawa, Fujisawa shall have the exclusive responsibility for any and all
regulatory matters for each Licensed Product in each country comprising the
Territory, including without limitation contacts (written or oral) with the
applicable regulatory agency and submission of any and all information and/or
documents to such regulatory agency.

                  (e)      Cooperation. DTI shall cooperate fully with Fujisawa
in Fujisawa's performance of its obligations under this Section 3.7, including
preparation for and participation with Fujisawa in responding to any
correspondence or requests received by Fujisawa from such regulatory authorities
to the extent DTI has relevant information or contributed to the regulatory
submission that is the subject of such inquiry.

         3.8      Back-up Compounds.

                  (a)      Selection of Back-up Compounds.

                           (i)      As required pursuant to Section 2.7, DTI
will provide to Fujisawa on the Effective Date all of its data and DTI Know-How
regarding its A1 Agonist Library. During the sixty (60) day period following the
Effective Date (the "Back-up Compound Notice Period"), DTI covenants that it
will not license (in whole or in part), conduct, fund, develop or participate
directly or indirectly through, one or more Third Parties the research,
development, distribution or commercialization in the Territory of any compound
in the A1 Agonist Library for use as an Injectable Product for any indication in
the Field (including without limitation PSVT and/or AFIB/F). During such Back-up
Compound Notice Period, Fujisawa may, at its option, provide written notice to
DTI designating up to three (3) compounds from the A1 Agonist Library as Back-up
Compounds. If Fujisawa so designates any Back-up Compound(s) during the Back-up
Compound Notice Period, DTI covenants that it will not license (in whole or in
part), conduct, fund, develop or participate in directly or indirectly through,
one or more Third Parties the research, development, distribution or
commercialization in the Territory of such Back-up Compound(s) for use as an
Injectable Product for any indication in the Field (including without limitation
PSVT and/or AFIB/F).

                           (ii)     If, after the expiration of the Back-up
Compound Notice Period, Fujisawa does not make any such designation of Back-up
Compounds, or designates less than three (3) Back-up Compounds, DTI may, subject
to the restrictions in Section 2.5, license, conduct, fund, develop or
participate in directly or indirectly through one or more Third Parties, the
research, development, distribution or commercialization of any of the remaining
compounds in the A1 Agonist Library (hereafter the "Remaining Compound(s)") for
any indications other than the Primary Indications and in any formulation other
than Injectable Products.

                           (iii)    At any time after the expiration of the
Back-up Compound Notice Period, and in the event Fujisawa has designated less
than three (3) Back-up Compounds during

                                       12

<PAGE>

the Back-up Compound Notice Period, Fujisawa may request in writing to designate
any Remaining Compounds as Back-up Compounds; provided, that the total number of
Back-up Compounds under this Agreement shall not exceed three (3). If Fujisawa
makes such Back-up Compound designation with respect to a Remaining Compound for
which DTI (or its sublicensee or contractee) has commenced Experimentation, then
(A) Fujisawa covenants that it will only develop and commercialize such Back-up
Compound(s) as Licensed Products to treat the Primary Indications in the
Territory and (B) the license grant to Fujisawa in Section 2.1 shall be
restricted with respect to any Licensed Product containing such Back-up Compound
such that DTI grants and Fujisawa accepts an exclusive (even as to DTI) license,
with right to sublicense as provided in Section 2.2, under the DTI Patents and
DTI Know-How to make, have made, sell, offer to sell, have sold, export and
import Licensed Products containing the selected Back-up Compound to treat only
the Primary Indications in the Territory. If, after the expiration of the
Back-up Compound Notice Period, Fujisawa designates as a Back-up Compound any
Remaining Compound for which DTI has not commenced Experimentation, then (A)
Fujisawa may develop and commercialize such Back-up Compound as a Licensed
Product in the Field pursuant to Section 3.8(b) and (B) the license grant to
Fujisawa in Section 2.1 shall not be restricted to Primary Indications and the
last sentence of Section 2.1 is not applicable in such event.

                           (iv)     In the event that DTI plans to undertake
development or commercialization of any Remaining Compound(s) with a Third
Party, it shall first provide written notice to Fujisawa along with the DTI
Know-How with respect to such Remaining Compound(s) as is reasonably necessary
for Fujisawa to assess its potential, and shall evaluate in good faith any offer
that Fujisawa makes to DTI with respect to Fujisawa's development and
commercialization of such Remaining Compound(s). Notwithstanding DTI's
disclosure obligation pursuant to Section 2.7 if DTI (or its sublicensee or
contractee) has commenced Experimentation for any Remaining Compound, DTI shall
not be required to provide Fujisawa with any additional DTI Know-How that DTI
develops with respect to any such Remaining Compound(s), except for DTI Know-How
that relates to the Primary Indications, in which case DTI shall be obligated to
disclose promptly such DTI Know-How.

                  (b)      Substitution of Back-up Compounds. If during its
development of the Licensed Products, Fujisawa determines that the Compound that
is the active ingredient in a Licensed Product then under development is not
suitable for further development into a therapeutic product for use in humans,
for safety, efficacy, or other reasons, Fujisawa may then substitute a Back-up
Compound in place of the Compound. Such Back-up Compound shall then be
considered a "Compound" for purposes of this Agreement. In such event, and where
the substituted Compound was under development for the Primary Indications, the
JMC shall discuss appropriate changes to the Development Plan to accommodate the
changes in the pre-clinical, clinical and regulatory schedule necessitated by
such substitution. If the Parties are unable to agree on such changes, Fujisawa
shall be entitled to exercise its right to cast the decisive tie breaking vote
with respect to all matters except for those subject to dispute resolution
pursuant to Section 3.5(c).

         3.9      Exchange of Information Between the Parties and Access to
Data. Following the Effective Date and subject to the licenses set forth in this
Agreement, each Party shall own all Data generated by such Party in the course
of performing its obligations under this Agreement.

                                       13

<PAGE>

Fujisawa agrees to provide to DTI the right to access, inspect and copy any and
all Data generated by or for Fujisawa under this Agreement (the "Fujisawa
Data"). DTI agrees to provide to Fujisawa the right to access, inspect and copy
any and all Data generated by or for DTI after the Effective Date in connection
with its (or its sublicensees', to the extent such Data is made available to DTI
to further provide to Fujisawa) development of the Compound and/or any Back-up
Compounds as Non-Injectable Products or as Injectable Products outside the
Territory (the "DTI Data"). The Parties acknowledge and agree that DTI Data does
not include any Data generated in connection with the Phase I Trial, which such
Data shall be part of the DTI Know How. Fujisawa hereby grants to DTI the right
to use the Fujisawa Data and to refer to any submissions by Fujisawa for
Regulatory Approval or any Master Files held by Fujisawa with respect to
Licensed Products, in connection with any submissions for Regulatory Approval of
the Non-Injectable Products and/or submissions for Regulatory Approval of the
Injectable Products in countries outside of the Territory. In consideration of
such grant to DTI, DTI shall pay royalties to Fujisawa as specified in Section
5.5. DTI hereby grants Fujisawa the right to use the DTI Data and to refer to
any submissions by DTI for Regulatory Approval or any Master Files held by DTI
with respect to Non-Injectable Products, or Licensed Products outside the
Territory, in connection with Fujisawa's submissions for Regulatory Approval of
the Licensed Product in the Territory. In consideration for such grant to
Fujisawa, Fujisawa shall pay royalties to DTI as specified in Section 5.6.
Fujisawa's Data and DTI's Data shall be treated as "Information" pursuant to
Section 10.

4.       COMMERCIALIZATION

         4.1      General. Fujisawa shall be responsible for commercializing the
Licensed Products in the Territory and Fujisawa shall use Diligent Efforts to
commercialize the License Products in the U.S. Fujisawa shall be solely and
exclusively responsible for any and all matters regarding the commercialization
of Licensed Products, including without limitation matters such as advertising,
promotion and promotional materials, marketing, pricing, distribution and
customer operations.

         4.2      Failure to Launch.

                 (a)       Subject to 4.2(b) and Section 11.5, if Fujisawa or
its sublicensee does not launch a Licensed Product for treatment of each of the
Primary Indications in the United States within nine (9) months after obtaining
Regulatory Approval of such Licensed Product for such Primary Indication in the
United States, or sooner notifies DTI that it will not launch such Licensed
Product for such Primary Indication in the United States, Fujisawa's rights
under this Agreement with respect to such Licensed Product for such Primary
Indication and in the United States shall terminate upon the earlier of such
notice or the 1 year anniversary of the grant of Regulatory Approval, and DTI
shall be free to commercialize such Licensed Product for such Primary Indication
in the Territory. In such event, Fujisawa shall promptly transfer to DTI all
INDs, applications for Regulatory Approval and Regulatory Approvals, or their
Canadian equivalents (as applicable) as it may hold with respect to such
Licensed Product for such Primary Indication, and any written information as
Fujisawa may possess which is useful to gain Regulatory Approval for and to
commercialize such Licensed Product in the Territory for such Primary
Indication. Such transfer

                                       14

<PAGE>

shall be without cost to DTI, provided however that DTI shall pay any
governmental filing or transfer fees that may be required.

                  (b)      Upon the occurrence of the events in Section 4.2(a),
Fujisawa shall also grant to DTI (i) an exclusive, fully-paid and royalty-free
(subject to DTI's obligations under Section 5.5) license under the Fujisawa
Technology to make, have made, use, import, export, offer for sale and sell such
Licensed Product for such Primary Indication in the U.S., and (ii) to the extent
it has the right to do so, a sublicense under any Third Party licenses to which
Fujisawa has rights, to the extent that such rights are necessary or useful to
make, have made, use, import, export, offer for sale and sell such Licensed
Product for such Primary Indication. DTI shall thereafter assume the cost of
maintaining its proportionate share of such Third Party license and shall
perform such obligations of Fujisawa under such license agreement as are
applicable to the relevant Licensed Products. To the extent such Third Party
license is no longer applicable or useful to Fujisawa, Fujisawa shall assign to
DTI all of its rights and obligations thereunder, rather than grant a sublicense
under, such license agreement.

         4.3      Distribution and Promotion.

                  (a)      Pricing and Product Distribution. Fujisawa shall have
the sole right to set prices for Licensed Products and shall obtain all pricing
approvals as may be required. Fujisawa shall also be solely and exclusively
responsible for distribution of the Licensed Products in the Territory.

                  (b)      Advertising and Promotion. Fujisawa will prepare or
have prepared, and have sole decision making authority over, any and all
advertising and education materials for the Licensed Products in the Territory.

         4.4      Trademarks. Fujisawa shall be responsible for developing,
registering, maintaining and defending any and all trademarks for the Licensed
Products, and shall own all such trademarks. Fujisawa shall, to the extent
practicable in Fujisawa's sole discretion, market and sell the Licensed Products
under a single trademark throughout the Territory. In the event that this
Agreement is terminated in its entirety pursuant to Section 11.4, upon the
request of DTI, the Parties shall negotiate in good faith the transfer or
license and the consideration therefor of all Fujisawa trademarks with respect
to the Licensed Products.

         4.5      Exchange of Adverse Event Information.

                  (a)      Within sixty (60) days of their respective
submission, Fujisawa shall provide DTI with copies of that portion of the IND
and NDA Annual Reports submitted by Fujisawa with the FDA and any other similar
reports submitted with the applicable regulatory authority in Canada that
address adverse event matters arising from the use of Licensed Products.
Fujisawa shall provide DTI with copies of IND Safety Reports within three (3)
days of their submission by Fujisawa to the FDA. Following Regulatory Approval
for each Licensed Product in the United States (and Canada if applicable),
Fujisawa shall provide DTI with copies of those Periodic Adverse Event Reports
submitted by Fujisawa to the FDA or other applicable regulatory authority in
Canada which relate to each Licensed Product. Such adverse event

                                       15

<PAGE>

reports shall be provided by Fujisawa to DTI within thirty (30) days of their
submission by Fujisawa to the FDA or such other regulatory authority.

                  (b)      Fujisawa shall provide DTI with copies of 15-Day
Alert Reports within three (3) days of their submission by Fujisawa to the FDA.
Fujisawa shall report these expedited reports on FDA MedWatch forms. Fujisawa
shall notify the contact person designated by DTI by fax at (804) 358-2451 or
telephone at (804) 358-9468, as may be revised.

         DTI shall be responsible for reporting to Fujisawa all serious adverse
event reports occurring with each Licensed Product during the Phase I Injectable
Protocol within three (3) days of receipt by DTI. Serious adverse events shall
be designated using the current FDA definition of the term "serious". DTI shall
provide Fujisawa with listings of all non-serious adverse events occurring with
each Licensed Product during the Phase I Trial annually and at the completion of
the study. Completion of a study shall be defined, for purposes of this Section
4.5(b) only, as that period of time one (1) week following Fujisawa's approval
of the final study report.

         After launch of the Licensed Products, DTI shall be responsible for
reporting to Fujisawa all serious adverse events associated with the Licensed
Products of which DTI becomes aware, whether within or outside the Territory,
within twenty four (24) hours after DTI becomes aware of such serious adverse
event. DTI shall notify Fujisawa of any non-serious adverse events associated
with the Licensed Products within the Territory of which DTI becomes aware
within ten (10) days of DTI becoming aware of the non-serious adverse event.

         DTI shall report to Fujisawa all serious adverse events associated with
the Non-Injectable Products during both clinical development and following
launch of the Non-Injectable Products, both within and outside the Territory,
within ten (10) days of DTI becoming aware of such serious adverse event.

         DTI shall report both serious and non-serious adverse events on forms
agreed upon by the Parties. DTI shall notify the contact person designated by
Fujisawa by fax at (847) 317-1241 or telephone at (800) 727-7003, as may be
revised.

         4.6      Regulatory Actions; Product Recalls; Product Withdrawals. In
the event (i) any government authority issues a request, directive or order that
any Licensed Product be recalled or withdrawn; (ii) a court of competent
jurisdiction orders such recall or withdrawal; or (iii) Fujisawa reasonably
determines that any Licensed Product should be recalled or withdrawn for any
reason, Fujisawa shall take all appropriate corrective actions requested by any
such government authority. DTI shall fully cooperate with Fujisawa in connection
with any such recall or withdrawal. In the event that such recall or withdrawal
results from the breach of and/or failure to comply with any of DTI's
obligations, representations and/or warranties under this Agreement, DTI shall
be solely responsible for the expenses of such recall or withdrawal. In the
event the recall or withdrawal results from any other reason, Fujisawa shall be
responsible for the expenses of the recall or withdrawal. For purposes of this
Agreement, the expenses of any such recall or withdrawal shall be all out of
pocket expenses incurred by either Party relative to the notification, shipping,
disposal and return of the recalled or withdrawn Licensed Product.

                                       16

<PAGE>

5.       PAYMENTS AND ROYALTIES

         5.1      License Fees. Fujisawa shall pay to DTI a nonrefundable,
noncreditable license issue fee of * upon execution of this Agreement.

         5.2      Development Costs. Within thirty (30) days of the Effective
Date, Fujisawa shall pay to DTI the amount set forth on Exhibit C, which
represents the actual development expenses incurred by DTI for the development
of the Compound after January 1, 1999 and prior to the Effective Date. Fujisawa
shall also reimburse DTI for the actual costs incurred by DTI in completing the
Phase I Trial, a budget for which is attached as Exhibit E. Within thirty (30)
days following the dosing of the last patient in the Phase I Trial, Fujisawa
shall reimburse DTI for * of its estimated costs set forth in such budget. The
remaining * (as may be adjusted up or down based upon actual costs as determined
by JMC) shall be paid within thirty (30) days of the receipt by Fujisawa of a
Final Clinical Study Report meeting the guidelines of the ICH (International
Conference on Harmonization). Fujisawa shall be responsible for paying all
additional development costs for the Licensed Product in accordance with the
terms and conditions of this Agreement.

         5.3      Milestones. Subject to the terms and conditions of this
Agreement, Fujisawa shall pay to DTI the following noncreditable and
nonrefundable amounts within thirty (30) days of the first achievement, by a
Licensed Product in the United States, of the respective milestone event set
forth below:

<TABLE>
<CAPTION>
                    Milestone Event                                  Payment
----------------------------------------------------------------     -------
<S>                                                                  <C>
(1) Reissuance of U.S. Patent No. 5,310,731                             *

(2) Completion of First Phase I Trial                                   *

(3) Completion of First Phase II Trial for the Licensed Product         *

(4) First Submission of a NDA for PSVT                                  *

(5) First Submission of a NDA for AFIB/F                                *

(6) First Regulatory Approval of a Licensed Product for PSVT            *

(7) First Regulatory Approval of a Licensed Product for AFIB/F          *
</TABLE>

Each milestone shall be paid only once; provided, however, that milestones need
not be achieved by the same Licensed Product (e.g., it may contain the Compound
or a Back-up Compound, or it may be developed for PSVT rather than AFIB/F) in
order to trigger a payment obligation under this Section 5.3. Milestones (1) -
(3) above shall be deemed "achieved" as follows:

                  (a)      Milestone (1) "Reissuance of U.S. Patent No.
5,310,731": Following Fujisawa's receipt of notice of the reissuance of U.S.
Patent No. 5,310,731, Fujisawa shall have thirty (30) days

-------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
-------------------------------------------------------------------------------

                                       17

<PAGE>

within which to either (i) pay Milestone (1) and maintain this Agreement in full
force and effect or (ii) terminate the Agreement in its entirety, in its sole
discretion, pursuant to Section 11.4(c), in which case it shall not be
responsible for paying Milestone (1) or any other milestone payment or any other
monies under this Agreement.

                  (b)      Milestone (2) "Completion of First Phase I Trial":
Once the last patient in the first Phase I Trial has been dosed, DTI shall be
deemed to have "completed" such trial, and Fujisawa shall pay Milestone (2)
within sixty (60) days after the date upon which the last such patient was
dosed. For purposes of clarity, it is understood that once the last patient is
dosed, Fujisawa shall be responsible for making such milestone payment; however,
in the event Fujisawa terminates this Agreement prior to such last patient being
dosed, Fujisawa shall not owe Milestone (2), nor any other milestone or any
other monies under this Agreement.

                  (c)      Milestone (3) "Completion of First Phase II Trial":
Within 30 days of the date upon which a "lock" is placed on the database for the
first Phase II Trial for the Licensed Product (regardless of whether such trial
involves PSVT or AFIB/F), Fujisawa will either (i) pay Milestone (3) and retain
this Agreement in full force and effect, or (ii) provide notice that it elects
to terminate the Agreement with respect to the particular Primary Indication
tested; provided, that in the event of Completion (as hereinafter defined) of
the first Phase II Trial for the remaining Primary Indication (or any other
indication, if occurring earlier), Fujisawa shall either (i) pay Milestone (3)
and retain this Agreement in full force and effect, or (ii) provide notice that
it elects to terminate this Agreement with respect to such remaining Primary
indication, subject to Section 11.5. For purposes of this Section 5.3(c),
"Completion of first Phase II Trial" for such remaining Primary Indication (or
other indication) shall mean occurrence of the 30/th/ day following the date
upon which a "lock" is placed on the database for such Phase II Trial. In the
event Fujisawa terminates this Agreement with respect to a particular Primary
Indication, it will not owe such milestone payment, or any other milestone
payment or other monies with respect to such terminated Primary Indication.

         5.4      Earned Royalties. Fujisawa shall pay DTI a running annual
royalty on aggregate, annual Net Sales of all Licensed Products in the
Territory, according to the following marginal rates:

                  (a)      For Net Sales of Licensed Products up to * of such
annual Net Sales; and

                  (b)      For the portion of Net Sales of Licensed Products in
excess of * and not exceeding * of such annual Net Sales; and

                  (c)      For the portion of Net Sales of Licensed Products in
excess of * of such annual Net Sales.

         5.5      Royalties to Fujisawa. If DTI (or its licensee or contractee)
uses or relies upon any Fujisawa Data (as described in Section 3.9) that is
contained in a Regulatory Approval application submitted by Fujisawa, in order
to obtain Regulatory Approval for either a Licensed Product outside the
Territory, any Non-Injectable Product or any product containing a compound from
the Al Agonist Library (hereafter, a "Fujisawa Data Product"), DTI shall pay to
Fujisawa a

-------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
-------------------------------------------------------------------------------

                                       18

<PAGE>

running royalty on annual Net Sales (as such term is defined pursuant to this
Section 5.5) of such Fujisawa Data Product according to the following marginal
rates:

         (a) For Net Sales of such Fujisawa Data Product up to * of such annual
Net Sales;

         (b) For the portion of annual Net Sales of such Fujisawa Data Product
in excess of * and not exceeding * of such annual Net Sales;

         (c) For the portion of Net Sales of such Fujisawa Data Product in
excess of * of such annual Net Sales;

provided, however, in no event shall the total royalty payments by DTI exceed *
times the actual costs borne by Fujisawa for the study(ies) which generated the
specific Data that is contained in Fujisawa's application for Regulatory
Approval and which DTI (or its licensee or contractee) uses or relies upon to
obtain Regulatory Approval for the particular Fujisawa Data Product. For
purposes of this Section 5.5, the term "Net Sales" shall have the same meaning
as provided in Section 1.28; provided, that (i) the word "Fujisawa" shall be
replaced by the word "DTI" and (ii) the word "Licensed Product(s)" shall be
replaced by the word "Fujisawa Data Product(s)".

         5.6      Additional Royalties to DTI. In addition to the royalty owed
on Licensed Products under Section 5.4, if Fujisawa (or its permitted
sublicensee) uses or relies upon any DTI Data (as described in Section 3.9) that
is contained in a Regulatory Approval application submitted by DTI, in order to
obtain regulatory approval for a Licensed Product in the Territory (hereafter, a
"DTI Data Product"), Fujisawa shall pay to DTI an additional running royalty, on
annual Net Sales (as such term is defined pursuant to this Section 5.6) of such
DTI Data Product according to the following marginal rates:

         (a) For Net Sales of such DTI Data Product up to * of such annual Net
Sales;

         (b) For the portion of Net Sales of such DTI Data Product in excess of
* and not exceeding * of such annual Net Sales;

         (c) For the portion of Net Sales of such DTI Data Product in excess of
* of such annual Net Sales;

provided, however, in no event shall the total royalty payments by Fujisawa
exceed * times the actual costs borne by DTI for the study(ies) which generated
the specific Data that is contained in DTI's application for Regulatory Approval
and which Fujisawa (or its sublicensee) uses or relies upon to obtain Regulatory
Approval for the particular DTI Data Product. For purposes of this Section 5.6,
the term "Net Sales" shall have the same meaning as provided in Section 1.28;
provided, that the word "Licensed Product(s)" shall be replaced by the word "DTI
Data Product(s)". The Parties acknowledge and agree that Fujisawa shall not owe
DTI any additional royalties under this Section 5.6 for any Data generated in
the Phase I Trial.

         5.7 Royalty Term. Fujisawa's obligation to pay royalties under Section
5.4 shall continue on a product-by-product basis (i) in the U.S. until five (5)
years after the expiration, lapse or

-------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
-------------------------------------------------------------------------------

                                       19

<PAGE>

invalidation by a decision of a court or tribunal of competent jurisdiction from
which no appeal is or can be taken of the last remaining DTI Patent (including
any extension thereof) which contains a valid and unexpired claim covering the
composition of matter or method of use of the relevant Licensed Product in the
U.S. and (ii) in Canada until the fifth (5th) anniversary of the date of the
first commercial sale of Licensed Product(s) in Canada (the "Royalty Term"). For
purposes of this Agreement "valid and unexpired claim" shall mean a composition
of matter or method of use claim or equivalent thereof, of an issued and
unexpired DTI Patent (or corresponding patent application, provided that the
original application containing such claim has not been pending for more than
years covering the relevant Licensed Product in such country, which (i) has not
been revoked or held unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal; or (ii) has not been abandoned, disclaimed, denied
or admitted to be invalid or unenforceable through reissue of disclaimer or
otherwise.

         5.8      Withholding Taxes. Any tax paid or required to be withheld by
a Party on account of royalties payable to the other Party under this Agreement
shall be deducted from the amount of royalties otherwise due. The withholding
Party shall secure and send to the other Party written proof of any such taxes
withheld and paid by the withholding Party or its sublicensees for the benefit
of the other Party. The withholding Party shall reasonably assist the other
Party in claiming exemption from such deductions or withholdings under any
double taxation or similar agreement or treaty from time to time in force.

         5.9      Blocked Currency. In each country where the local currency is
blocked and cannot be removed from the country, at the election of the Party
paying royalties, royalties accrued in that country shall be paid to the other
Party in the country in local currency by deposit in a local bank designated by
the other Party.

         5.10     Royalty Payments and Reports. Beginning with the first
commercial sale of a Licensed Product, royalties shall accrue on Fujisawa's
fiscal quarter basis. The royalty-paying Party shall pay all amounts owed within
forty-five (45) days following the end of the relevant calendar quarter. Each
royalty payment shall be accompanied by a report summarizing the number,
description, and aggregate sales of Licensed Products made and the royalty
payable thereon according to Sections 5.4, 5.5, and 5.6 respectively, including
a description of any offsets or credits deducted from such sales, on a
product-by-product and country-by-country basis during the relevant three-month
period. For any given royalty period, the royalty-paying Party shall pay the
royalty at the rate specified in Section 5.4, 5.5, or 5.6 applicable to the then
current year-to-date Net Sales level. Each statement provided at the end of the
fourth quarter of each year shall contain a reconciliation of actual royalty
payments made during that year and the amount actually owed for such year
according to that year's Net Sales level, and the resulting amount, if any,
shall be paid at the time of such fourth quarter statement, in accordance with
the terms of this Section 5.10. The royalty-paying Party may credit any amounts
paid in excess of the amount actually owed against future quarterly royalty
payments.

         5.11     Currency; Exchange Rate. Subject to Section 5.9, all amounts
paid under this Agreement shall be paid in U.S. dollars to either Party by wire
transfer to a financial institution to be designated by the Party to whom
payment is owed. The royalty on sales by either Party or

                                       20

<PAGE>

their respective sublicensee(s) of Licensed Products sold in a currency other
than United States Dollars shall be converted into United States Dollars using
the selling rate of exchange for the currency of the country from which the
royalties are payable as published by the Wall Street Journal, New York, N.Y.,
U.S.A., for the last business day of the quarterly period for which the
royalties are due.

         5.12     Accounting. Each Party agrees to keep and maintain such
records, using generally accepted accounting principles (GAAP) consistently
applied, as it normally generates in the ordinary course of its business for a
period of three (3) years showing the sale, use, and other disposition of
products sold or otherwise disposed of under the license herein granted. Such
records shall be kept in sufficient detail to enable the royalties payable
hereunder by either Party to be determined. Each Party further agrees to permit
its books and records to be examined by an independent certified public
accountant selected by the other Party, at ordinary business hours with
reasonable prior notice and not more than once per year, to the extent necessary
to verify reports and payments provided for in this Agreement. Following
completion of the Phase I Trial, Fujisawa may audit DTI's books with respect to
any costs incurred by DTI and reimbursed by Fujisawa, including, without
limitation, pre-clinical, and Phase I Trial expenses, and those incurred and
reimbursed under Section 2.7, along with such Phase I Trial. No copies of either
Party's records shall be copied or retained by such examiner. Such examination
is to be made under appropriate confidentiality restrictions, at the expense of
the auditing Party, except in the event that the results of the audit reveal an
underreporting of royalties due to the auditing Party of * or more in any year,
then the audit costs shall be paid by the audited Party.

6.       MANUFACTURING

         6.1      General. DTI will be responsible for obtaining sufficient
quantities of Licensed Products necessary for it to conduct the Phase I Trial.
Fujisawa will be responsible for identifying a suitable manufacturer, developing
commercial manufacturing processes and supplying subsequent clinical and
commercial quantities of Licensed Products for distribution and sale in the
Territory. DTI will cooperate with Fujisawa in connection with such third party
manufacturer.

         6.2      Quality Assurance. Fujisawa shall have day to day
responsibility for commercial manufacturing and formulation issues related to
product safety and regulatory compliance. All Licensed Products used in clinical
and commercial supplies will be manufactured, tested, and released according to
current cGMP's and all other applicable law and regulatory requirements of the
country in which such Licensed Products are to be used or distributed and sold.
Both parties will be responsible for maintaining its facilities and procedures,
including those of Third Parties, in material compliance with cGMP's and
applicable laws and regulatory requirements. The Parties will promptly notify
each other in advance, if known, of any governmental regulatory inspections and,
within twenty four (24) hours of any such inspection, shall provide the other
Party with the results of any governmental regulatory inspections or other
governmental regulatory action concerning the facilities or other manufacturing
or formulation issues, copies of all Form FD 483's (or their non-U.S.
equivalents) and compliance related documentation, including all actions taken
by a Party in response thereto

                                       21

<PAGE>

or as a result thereof. Any expenses incurred in improving compliance with
applicable regulatory requirements or responding to Form FD 483's (or their
non-U.S. equivalents) or other compliance-related documentation will be the full
responsibility of Fujisawa.

7.       REPRESENTATIONS AND WARRANTIES; DISCLAIMERS

         7.1      Representations and Warranties.

                  (a)      Each Party hereby represents and warrants to the
other that this Agreement is a legal and valid obligation binding upon such
Party and enforceable in accordance with its terms, and that the execution,
delivery and performance of this Agreement by such Party does not conflict with
any agreement, instrument or understanding, oral or written, to which it is a
Party or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.
Each Party expressly represents and warrants that it has full right, power and
authority to execute and deliver this Agreement and to perform their respective
obligations contemplated hereby.

                  (b)      DTI hereby represents and warrants to Fujisawa that:

                           (i)      No consent of any Third Party is required
for DTI to grant the exclusive license to Fujisawa under Section 2.1, to enter
into this Agreement and/or to perform its obligations hereunder.

                           (ii)     DTI owns, or controls (with the right to
grant sublicenses consistent with those granted Fujisawa hereunder) the DTI
Patents and DTI Know-How.

                           (iii)    DTI has not, and during the term of the
Agreement will not, grant any right to a Third Party under the DTI Patents and
DTI Know-How in the Field that would conflict with any of the rights granted to
Fujisawa under this Agreement.

                           (iv)     DTI has not to its knowledge received any
communication or claim from, or by any Third Party, nor is otherwise aware of,
any issue relative to the validity, enforceability or infringement of any of the
DTI Patents and/or that the practice of the inventions claimed in the DTI
Patents and/or comprising the DTI Know-How infringe the rights of any Third
Party.

                           (v)      To the best of DTI's knowledge, there is no
prior art that has not been cited by DTI to the PTO which would invalidate the
DTI Patents. The DTI Patents have not been obtained through any
misrepresentation that would affect or destroy the validity and/or
enforceability of the DTI Patents.

                           (vi)     There are no claims currently asserted or,
to the best of DTI's knowledge, threatened by any Third Party involving,
questioning and/or relative to: (i) Fujisawa's right to use and/or receive from
DTI the exclusive license under this Agreement; and/or (ii) DTI's ability to
enter into this Agreement and perform its obligations hereunder.

                                       22

<PAGE>

                           (vii)    As of the Effective Date, it has not
received any notices that the manufacture, use, sale or importation of the
Compound or the Back-up Compounds infringe the intellectual property rights of
any Third Party.

                           (viii)   The U.S. Patent No. 5,310,731 is the subject
of a reissue application to correct a defect with respect to certain claims in
such U.S. Patent. Except with respect to this defect and to the best of DTI's
knowledge, the DTI Patents are valid and enforceable, and there has been no
lapse in any of rights provided by the DTI Patents.

                           (ix)     DTI represents and warrants that to the best
of its knowledge DTI has disclosed to Fujisawa all material information in DTI's
possession or control concerning side effects, injury, toxicity or sensitivity
reaction and incidents associated with the use of Licensed Products obtained
from any non-clinical studies.

                           (x)      DTI has conducted all pre-clinical studies
for the Compound, the Back-up Compounds and the Licensed Products, if any
(collectively "DTI's Pre-Clinical Studies") in substantial compliance with Good
Laboratory Practices and all applicable Federal, state and local laws, rules,
regulations and guidelines governing the conduct of pre-clinical studies. To the
best of DTI's knowledge, neither DTI nor any of the investigators, institutions,
laboratories, clinical research organizations or other individuals or entities
participating in DTI's Pre-Clinical Studies have been or are "debarred" as such
term is used in Section 335a of the United States Code. Any and all necessary
financial disclosures have been obtained in accordance with 21 CFR Part 54, from
the investigators and/or institutions participating in DTI's Clinical Studies,
to the extent applicable.

         7.2      Warranty Disclaimer. EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER
REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED WITH RESPECT TO THE
COMPOUND, THE BACK-UP COMPOUNDS OR THE LICENSED PRODUCTS. EXCEPT AS PROVIDED
ABOVE, THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS
FOR A PARTICULAR PURPOSE OR THAT THE USE OF THE LICENSED PRODUCT(S) WILL NOT
INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS, OR ANY
OTHER EXPRESS OR IMPLIED WARRANTIES.

         7.3      IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY
INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, INCURRED BY EITHER PARTY
AND ARISING FROM PERFORMANCE OR NONPERFORMANCE UNDER THIS AGREEMENT, WHETHER
BASED ON AN ACTION IN CONTRACT OR TORT - OR BASED ON A WARRANTY.

8.       INDEMNITY AND INSURANCE

         8.1      Indemnification by Fujisawa. Fujisawa hereby agrees to
indemnify, defend and hold harmless DTI and its agents and employees from and
against any and all Third Party suits, claims, actions, demands, liabilities,
expenses and/or loss, including reasonable attorneys' fees and costs (such Third
Party suits, claims, actions, demands, liabilities, expenses and/or loss,

                                       23

<PAGE>

including reasonable attorneys' fees and costs shall be referred to herein as
"Losses") resulting from (a) Fujisawa's breach of any of its obligations,
agreements, covenants, representations and/or warranties hereunder; (b) any use
of DTI's Data (except where such Data is either fraudulent or otherwise does not
meet the requirements of applicable rules, regulations and/or law) and/or (c)
the manufacture, use, handling, storage, sale or other disposition of Licensed
Products by Fujisawa, its agents, representatives, consultants or sublicensees
except to the extent such Losses result from (i) the negligence or wrongdoing of
DTI, its agents, representatives, consultants or employees, or (ii) from the
actions or inactions of DTI, its agents, representatives, consultants or
employees for which DTI is obligated to indemnify Fujisawa pursuant to Section
8.2.

         8.2      Indemnification by DTI. DTI hereby agrees to indemnify, defend
and hold harmless Fujisawa and its agents and employees from and against any and
all Losses resulting from (a) DTI's breach of any of its obligations,
agreements, covenants, representations and warranties hereunder; (b) any use of
Fujisawa's Data (except where such Data is either fraudulent or otherwise does
not meet the requirements of applicable rules, regulations and/or law); and/or
(c) any use of Data generated by or on behalf of DTI in the Phase I Trial which
is either fraudulent or otherwise does not meet the requirements of applicable
rules, regulations and/or law; except to the extent such Losses result from (i)
the negligence or wrongdoing of Fujisawa, its agents, representatives,
consultants or employees, or (ii) the actions or inactions of Fujisawa, its
agents, representatives, consultants or employees for which Fujisawa is
obligated to indemnify DTI pursuant to Section 8.1.

         8.3      Indemnification Procedure. If a Party (in this context, the
"Indemnified Party" seeks indemnification under the applicable provision of this
Section 8, the Indemnified Party shall promptly notify the other Party (in this
context, the "Indemnifying Party") of its claim for indemnification
("Indemnified Claim"), but in no event more than ten (10) business days after
the Indemnified Party has been served with legal process or otherwise received
notice of the commencement of any action by a third party; provided, however,
that the right of the Indemnified Party to indemnification shall be reduced in
the event of its failure to give timely notice only to the extent the
Indemnifying Party is prejudiced thereby. The Indemnified Party shall defend the
Indemnified Claim. The Indemnified Party may retain separate co-counsel at its
sole cost and expense and participate in the defense of the Indemnified Claim.
The Indemnified Party shall fully cooperate with the Indemnifying Party's
defense of any Indemnified Claim, including without limitation providing any and
all required knowledge and documents and access to its employees.

         8.4      Insurance. In addition to the foregoing, both Parties shall
obtain appropriate insurance in accordance with standard commercial practices to
cover their respective indemnities granted in Sections 8.1 and 8.2. Each Party
agrees to provide evidence of such coverage if requested by the other Party.

9.       PROTECTION OF PATENTS; CLAIMS OF INFRINGEMENT

         9.1      Ownership of Intellectual Property. Each Party shall solely
own inventions made within and outside of the United States by that Party's
employees or agents or consultants

                                       24
<PAGE>

in the course of performing any work under this Agreement. Inventions made
jointly by employees, agents or consultants of DTI and Fujisawa shall be owned
jointly by DTI and Fujisawa, with each party retaining an undivided one-half
interest in such jointly-developed inventions pursuant to Section 9.5. The law
of ownership of inventions of the United States shall apply to any patents filed
or issued outside the United States claiming inventions of the Parties. For all
inventions under this Section 9.1, the Parties shall provide reasonable
assistance to each other in perfecting title to such inventions.

         9.2      Infringement of DTI Patents.

                  (a)      Each Party shall promptly notify the other in writing
of any alleged or threatened infringement of any DTI Patents in the U.S. Both
Parties shall use their commercially reasonable efforts in cooperating with each
other to terminate such infringement.

                  (b)      Subject to Section 9.2(e), Fujisawa shall have the
first right to bring and control any action or proceeding with respect to
infringement of a DTI Patent in the U.S., to the extent such infringement
involves a product which is an Injectable Product that is competitive with a
Licensed Product, at its own expense and by counsel of its own choice. DTI shall
have the right, at its own expense, to be represented in any such action
involving a DTI Patent. If Fujisawa fails to bring an action or proceeding with
respect to such infringement within: (b) (i) ninety (90) days following the
notice of alleged infringement or (ii) ten (10) days before the time limit, if
any, set forth in the appropriate laws and regulations for the filing of such
actions, whichever comes first, it shall notify DTI and DTI shall have the right
to bring and control any such action at its own expense and by counsel of its
own choice, subject to Section 9.2(e). Prior to providing such notification to
DTI, Fujisawa shall take any action (or cause to be taken any action) necessary
to reasonably ensure that the rights of DTI under any such action are not
prejudiced, including but not limited to filing a responsive pleading or
obtaining an extension of time to do so. Fujisawa shall have the right, at its
own expense, to be represented in any such action by counsel of its own choice.

                  (c)      DTI (or its licensee) shall have the first right to
bring and control any action or proceeding with respect to infringement of a DTI
Patent in the U.S., to the extent such infringement involves a product which is
a Non-Injectable Product, or is an Injectable Product, but is not competitive
with a Licensed Product, at its own expense and by counsel of its own choice.
Fujisawa shall have the right, at its own expense, to be represented in any such
action by counsel of its own choice, where such action involves an Injectable
Product. If DTI (or its licensee) determines not to pursue an infringement
action under this Section 9.2, it shall promptly notify Fujisawa, and Fujisawa
shall have the right to bring and control any such action at its own expense and
by counsel of its own choice, subject to Section 9.2(e). Prior to providing such
notification to Fujisawa, DTI shall take any action (or cause to be taken any
action) necessary to reasonably ensure that the rights of Fujisawa under any
such action are not prejudiced, including but not limited to filing a responsive
pleading or obtaining an extension of time to do so. Fujisawa may elect, but
shall not be obligated, to bring, at its own expense, any such action DTI (or
its sublicensee) elects not to bring. DTI (and its sublicensee) shall have the
right, at its own expense, to be represented in any such action involving a DTI
Patent which Fujisawa brings under this Section 9.2(c).

                                       25

<PAGE>

                  (d)      In the event a Party brings an infringement action
against a Third Party, the other Party shall cooperate fully, including, where
necessary, joining the action as a Party plaintiff. Neither Party shall have the
right to settle any patent infringement litigation under this Section 9.2
without the prior written consent of such other Party. If there is no agreement
between the Parties as to any proposed settlement, then the dispute shall be
resolved pursuant to Article 13.

                  (e)      Any recovery realized as a result of such litigation,
after reimbursement of any litigation expenses for Fujisawa and DTI, shall
belong to the Party bringing the litigation; provided, however, if Fujisawa
recovers damages as a result of such litigation that are attributable to lost
sales of Licensed Products, such amounts shall be treated as if they were Net
Sales and Fujisawa shall pay to DTI the royalties due under Section 5.4 as if
such amounts were Net Sales of such Licensed Products.

         9.3      Defense and Settlement of Third Party Claims of Patent
Infringement.

                  (a)      General. If a Third Party asserts against Fujisawa or
DTI that a patent, trademark or other intangible right owned by it is infringed
by the manufacture, use or sale of any Licensed Product manufactured or sold in
the Territory by Fujisawa or its sublicensee, each Party will promptly notify
the other in writing and Fujisawa shall be solely responsible for (a) defending
such action, subject to the requirements of this Section 9.3, and subject to
Section 9.3(b) Fujisawa shall pay any and all costs, expenses (including
attorneys' fees and costs) fees, license fees, payments, royalties and expenses
in connection with such defense and/or settlement.

                  (b)      Royalty Offset. Fujisawa may credit against the
royalty payments owed to DTI under Section 5.4 for sales of Licensed Products *
of all of its costs, expenses, fees (including attorneys' fees and costs),
license fees, payments, royalties and any other amounts expended to defend or
settle such action and/or obtain a license; provided, that the maximum amount of
credit that Fujisawa may apply against such royalty payments in any given
quarter shall not exceed * of the royalty payment owed in such quarter (the
"*"). Any amounts in excess of the * Threshold for any prior quarter may be
credited against subsequent quarterly royalty payments owed to DTI, subject to
the * Threshold limitation for any such subsequent quarter, until the total
amount has been credited.

                  (c)      Settlement with a Third Party. The entity that
controls the defense of a given claim with respect to a Licensed Product shall
also have the right to control settlement of such claim; provided, however, that
no settlement shall be entered into without the prior written consent of the
other Party. If there is no agreement between the Parties as to any proposed
settlement, then the dispute shall be resolved pursuant to Article 13.

         9.4      Prosecution and Maintenance of DTI Patents. DTI shall be
responsible for obtaining the re-issuance of U.S. Patent No. 5,310,731 and
maintaining all DTI Patents. DTI shall keep Fujisawa informed as to the status
of the reissuance and shall promptly provide copies of any and all documentation
and correspondence to and from the PTO. Fujisawa shall reimburse DTI for all of
its reasonable expenses incurred after the Effective Date for prosecuting and
maintaining the DTI Patents (other than costs in connection with the reissuance)
in the United States until such time as DTI commercializes a Non-Injectable
Product in the United States, at which point

--------------------------------------------------------------------------------
 * Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       26

<PAGE>

Fujisawa shall be responsible for reimbursing DTI for fifty percent (50%) of its
expenses for maintaining DTI Patents. DTI shall notify Fujisawa if it intends to
abandon any DTI Patent or other patent covering the Licensed Product at least
sixty (60) days prior to any relevant deadline. Fujisawa shall have the right,
at its own expense and under its own name, to file and assume prosecution and
maintenance of any patent or patent application abandoned by DTI, and all rights
under such abandoned DTI Patent or other patent shall revert or be assigned by
DTI to Fujisawa.

         9.5      Prosecution and Maintenance of Joint Patents. For all patents
claiming jointly owned inventions ("Jointly Owned Patents"), the Parties shall
work together to develop a reasonable patent strategy appropriate for the
technology at issue. DTI shall have the first right, but not the obligation, to
prosecute and maintain any Jointly Owned Patents. DTI shall permit Fujisawa to
review and comment on any documents filed with the relevant patent authorities
in the Territory with respect to any Jointly Owned Patents. Fujisawa shall
reimburse DTI for fifty percent (50%) of its expenses in prosecuting and
maintaining Jointly Owned Patents in the Territory; provided, however, that
Fujisawa may elect to forego its ownership interest in such Jointly Owned Patent
application during the sixty (60) day period following the filing of such
application, in which case it shall not reimburse DTI and shall assign over its
interest. If DTI elects not to prosecute a Jointly Owned Patent, or to abandon
any Jointly Owned Patent, it shall provide sixty (60) days written notice to
Fujisawa prior to any relevant deadline and Fujisawa shall have the right, but
not the obligation, to prosecute and maintain such patent at Fujisawa's expense,
and under its own name. DTI shall have the right to grant licenses under any
Jointly Owned Patents to any Third Party without the consent of Fujisawa,
subject to the license in Section 2.1. Fujisawa shall have the right to grant
licenses under any Jointly Owned Patents (i) to any Third Party to make, have
made, use, import, export, offer for sale and sell Licensed Products without the
consent of DTI, but only so long as this Agreement is in effect, and only in
connection with a sublicense permitted under Section 2.2 and (ii) to any Third
Party for any other use, without the consent of DTI.

10.      CONFIDENTIALITY

         10.1     Information. Each Party shall keep all information received
from the other Party (the "Information") confidential and shall not disclose nor
use the Information without the other Party's written consent except to the
extent contemplated by this Agreement. This restriction shall not, however,
prevent disclosure of the Information if and to the extent that disclosure is
required by law, provided that the disclosing Party informs the other Party
without delay of any such requirement, in order to allow such other Party to
object to such disclosure and to seek an appropriate protective order or similar
protection prior to disclosure.

         10.2     Exceptions. The above obligations shall not apply or shall
cease to apply to Information which:

                  (a)      is now, or hereafter becomes, through no act or
failure to act on the part of the receiving Party, generally known or available
to the public;

                  (b)      is known by the receiving Party at the time of
receiving such information, as evidenced by its written records;

                                       27

<PAGE>

                  (c)      is hereafter furnished to the receiving Party by a
third party, as a matter of right and without restriction on disclosure;

                  (d)      is independently developed by the receiving Party
without any breach of this Section 10 as is evidenced by written records; or

                  (e)      is the subject of a written permission to disclose
provided by the disclosing Party.

         10.3     Permitted Disclosures. Information may be disclosed for the
purpose of filing, prosecuting and maintaining the DTI Patents, for obtaining
Regulatory Approvals, and to employees, agents, consultants, Third Party
contract manufacturer, sublicensees or suppliers of the recipient Party, but
only to the extent required to accomplish the purposes of this Agreement and
only if such individuals are required by law, contract or otherwise not to use
or disclose such information except as permitted by this Agreement. Each Party
will use at least the same standard of care as it uses to protect proprietary or
confidential information of its own to ensure that such employees, agents,
consultants, sublicensees or suppliers do not disclose or make any unauthorized
use of the Information.

         10.4     Disclosure of Agreement; Press Releases. Except as required by
law, neither DTI nor Fujisawa shall release to any Third Party or publish in any
way any non-public information with respect to the terms of this Agreement
without the prior written consent of the other; provided; however that either
Party may disclose the terms of this Agreement to the extent required to comply
with applicable laws, including without limitation the rules and regulations
promulgated by the Securities and Exchange Commission. Notwithstanding any other
provision of this Agreement, each Party may disclose the terms of this Agreement
to lenders, investment bankers, financial advisors and other financial
institutions of its choice solely for purposes of financing the business
operations of such Party, or to potential investors in or acquirors of such
Party either (i) upon the written consent of the other Party or (ii) if the
disclosing Party obtains a signed confidentiality agreement with such intended
recipient with respect to such information, upon terms substantially similar to
those contained in this Section. Notwithstanding the foregoing, promptly
following execution of this Agreement the Parties will issue mutually agreed
upon press release(s). Any future press releases or other public disclosures
cannot be made by one Party without the prior written consent of the other
Party, with the understanding that Fujisawa will have sole decision making
authority to the extent any such press release covers the Licensed Product,
except to the extent required by law and except when the information has already
been publicly disclosed in a prior press release or filing required under the
Securities and Exchange Act.

11.      TERM AND TERMINATION

         11.1     Term. This Agreement shall commence on the Effective Date and
expire at the end of the Royalty Term under Section 5.7. Upon the expiration
(but not the earlier termination) of the Royalty Term, the licenses granted
hereunder to Fujisawa shall convert to non-exclusive, fully paid and
royalty-free licenses.

                                       28

<PAGE>

         11.2     Early Termination for Material Breach. If either Party commits
a material breach of this Agreement and such breach is not cured within ninety
(90) days after written notice thereof by the non-breaching Party, or if such
breach is incapable of cure during the applicable notice period, the breaching
Party fails to make good faith efforts to cure such breach, the non-breaching
Party may terminate this Agreement upon expiration of the notice period.
Notwithstanding the foregoing, any termination by DTI under this Section 11.2
for a material breach by Fujisawa shall only be effective as to the particular
Licensed Product at issue, and for the particular indication for which it was
under development or being sold, except for material breach of Sections 2.1,
2.6, 3.8(a)(iii), 3.9, 5.3, 5.4, 5.6, and 10.1, in which case the entire
Agreement may be terminated by DTI.

         11.3     Termination for Bankruptcy. All rights and licenses granted
under or pursuant to this Agreement by DTI to Fujisawa are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses
of rights to "Intellectual Property" as defined under Section 101(56) of the
Bankruptcy Code. The Parties agree that Fujisawa, as a licensee of such rights
and licenses, shall retain and may fully exercise all of its rights and
elections under the Bankruptcy Code. The parties further agree that, in the
event that any proceeding shall be instituted by or against DTI seeking to
adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up,
reorganization, arrangement, adjustment, protection, relief or composition of it
or its debts under any law relating to bankruptcy, insolvency or reorganization
or relief of debtors, or seeking an entry of an order for relief or the
appointment of a receiver, trustee or other similar official for it or any
substantial part of its property or it shall take any action to authorize any of
the foregoing actions (each a "Proceeding"), Fujisawa shall have the right to
retain and enforce its rights under this Agreement to the full extent under
applicable law, including without limitation, any rights under Section 365(n) of
the Bankruptcy Code.

         11.4     Early Termination by Fujisawa.

                  (a)      Termination for Safety. Subject to Section 11.6,
Fujisawa may terminate this Agreement in whole or in part (i.e., with respect to
a particular Licensed Product and/or indication) at any time upon thirty (30)
days prior written notice if: Fujisawa determines that there are safety concerns
regarding the Licensed Products such that no Licensed Product could reasonably
be developed that would meet Fujisawa's standards for product safety, so long as
such determination is made in good faith and that Fujisawa applies the same
standards to evaluate the safety of Licensed Products as it typically and
customarily would apply for the safety evaluation of other products, including
products derived from its own research and development efforts, at similar
stages of development. In the event Fujisawa terminates under this Section
11.4(a), it would not owe any milestone payment that became due during the
thirty (30) day notice period, or any other monies hereunder with respect to the
terminated Licensed Product and/or indication, except for Milestone (2) under
Section 5.3(b) in accordance with the terms thereof, where such termination
occurred after the dosing of the last patient in the Phase I Trial.

                  (b)      Termination for Other Scientific Reasons. Subject to
Section 11.6, Fujisawa may terminate this Agreement in whole or in part (i.e.,
with respect to a particular Licensed Product and/or indication) upon ninety
(90) days prior written notice if: it determines

                                       29

<PAGE>

not to continue further research and development for reasons concerning
efficacy, dosing regimen or formulation, so long as such determination is made
in good faith and that Fujisawa applies the same standards to evaluate such
factors with respect to Licensed Products as it typically and customarily would
apply for the similar evaluation of other products, including products derived
from its own research and development efforts, at similar stages of development.
In the event Fujisawa terminates under this Section 11.4(b), it would not owe
any milestone payment that became due during the ninety (90) day notice period,
or any other monies hereunder with respect to the terminated Licensed Product
and/or indication, except for Milestone (2) under Section 5.3(b) in accordance
with the terms thereof, where such termination occurred after the dosing of the
last patient in the Phase I Trial.

                  (c)      Termination for Non-Issuance of Valid DTI Patent.
Fujisawa may terminate this Agreement in its entirety for non-issuance of the
DTI Patent pursuant to Section 5.3(a).

                  (d)      Termination for Other Patent Issues. Fujisawa may
terminate this Agreement in its entirety upon thirty (30) days prior written
notice if it determines in good faith after receiving an opinion of outside
patent counsel, that the manufacture, use, distribution or sale of any of the
Licensed Products would likely infringe any patent that issues in the United
States and/or Canada after the Effective Date.

                  (e)      Termination for Convenience. After two (2) years from
the Effective Date, Fujisawa may at its sole discretion elect to terminate this
Agreement in its entirety for any reason at any time upon thirty (30) days prior
written notice. In the event Fujisawa terminates under this Section 11.4(e), it
would not owe any milestone payment that became due during the thirty (30) day
notice period or any other monies hereunder, except for Milestone (2) under
Section 5.3(b) in accordance with the terms thereof, where such termination
occurred after the dosing of the last patient in the Phase I Trial.

                  (f)      Obligations During Termination Notice Period. If
Fujisawa terminates this Agreement pursuant to Section 11.4(a), (b) or (c), it
shall not be obligated, during the applicable termination notice period in
Section 11.4 (a), (b) or (c), to perform its obligations under Sections 3.5,
3.7, 4.1 and 4.2 of this Agreement.

         11.5     Termination of Entire Agreement. Notwithstanding Section
3.5(b), 3.6, 4.2(a), 5.3(c), 11.4(a), or 11.4(b), in the event Fujisawa's rights
to both Primary Indications are terminated (i) by DTI pursuant to Section
3.5(b), 4.2(a) or 11.2 or (ii) by Fujisawa pursuant to Section 3.6, 5.3(c) or
11.4(a) or 11.4(b), and in the further event that Fujisawa has not commenced
development with respect to the Licensed Product for any other indication in the
Field at the time of such termination, then DTI shall also have the right to
terminate this Agreement in its entirety, in which case Fujisawa's rights, to
the extent they exist, to make, have made, use, sell, offer for sale, import and
export Licensed Products for all other indications in the Field shall terminate
and Section 11.7 shall apply.

         11.6     Effect of Partial Termination. In the event there is any
termination under this Agreement (including without limitation any termination
provided for under Section 3.5(b), 3.6, 4.2(a), 5.3(c), 11.2, 11.4(a) or
11.4(b), where such termination is only effective as to a particular

                                       30

<PAGE>

Licensed Product and/or certain indication for such Licensed Product, the
Parties acknowledge and agree that with respect to any other Licensed Product
and/or indication licensed at such time to Fujisawa under this Agreement, the
terms and conditions of this Agreement shall remain in full force and effect,
subject to Section 11.5.

         11.7     Effect of Early Termination.

                  (a)      In the event Fujisawa terminates this Agreement
pursuant to Section 11.4(a) or 11.4(b) and the Phase I Trial is not concluded as
of the effective date of such termination, Fujisawa shall be obligated to
reimburse DTI under Section 5.2 only for the costs of such Phase I Trial
incurred up to the effective date of such termination; provided, however, that
Fujisawa shall nonetheless reimburse DTI for all costs owed to a Third Party
which could not be canceled by DTI and reasonably incurred by DTI through the
completion of the Phase I Trial. DTI shall use reasonable commercial efforts to
negotiate a cancellation of such costs.

                  (b)      In the event that Fujisawa terminates this Agreement
pursuant to Section 11.4(a), (b), (c), (d) or (e), or either Party terminates
for material breach under Section 11.2, the following shall apply:

                           (i)      all licenses to Fujisawa with respect to
Licensed Products shall terminate (or, where partially terminated, the Licensed
Product and/or indication at issue);

                           (ii)     except in the event Fujisawa terminates for
DTI's material breach under Section 11.2, Fujisawa hereby grants to DTI a
royalty-free (Except for those royalties provided in Section 5.5), non-exclusive
license under the Fujisawa Technology to make, have made, use, sell, have sold,
export and import Licensed Products worldwide, in the Field (or, where partially
terminated, the Licensed Product and/or indication at issue);

                           (iii)    Fujisawa and DTI shall cooperate to ensure
that the development and commercialization of Licensed Products in the Territory
continues with a minimum of delay resulting from the transfer of rights back to
DTI. Fujisawa shall promptly transfer to DTI at DTI's written request all
Fujisawa Technology and assign all INDs, applications for Regulatory Approval
and Regulatory Approvals, or their Canadian equivalents (as applicable) as it
may hold with respect to such Licensed Product(s) in the Territory, and any
information as Fujisawa may possess which is useful to gain Regulatory Approval
for and to commercialize such Licensed Product(s) in such country. In the event
such assignment is not permitted by law, Fujisawa will cooperate in the
cancellation of such government approval, clearance, registration or permit
standing in its name and the reissuance of such government approval, clearance,
registration or permit to DTI or its designee. Such transfer shall be without
cost to DTI, provided however that DTI shall pay any governmental filing or
transfer fees that may be required;

                           (iv)     to the extent it has the right to do so,
Fujisawa shall grant to DTI a sublicense under any Third Party licenses to which
Fujisawa has rights, to the extent that such rights are necessary or useful to
make, have made, use, import, offer for sale and sell such Licensed Product. DTI
shall thereafter assume the cost of maintaining its proportionate share of such
sublicenses and shall perform such obligations of Fujisawa under such license
agreement as are applicable to the relevant Licensed Product. To the extent such
Third Party license is no

                                       31

<PAGE>

longer applicable or useful to Fujisawa, Fujisawa shall assign to DTI all of its
rights and obligations, rather than grant a sublicense under, such license
agreement; and

                           (v)      Fujisawa shall take all such other
reasonable actions and execute such other instruments, assignments and documents
as may be necessary to effect the transfer of rights hereunder.

Notwithstanding the foregoing, it is expressly understood and agreed that the
foregoing provisions regarding license terminations, transfer of data,
assignment of regulatory filings and the like shall only be effective as to the
particular Licensed Product at issue, and for the particular indication for
which it was under development or being sold, where this Agreement is terminated
in part as provided for in this Agreement.

                  (c)      At the time of any early termination, if Fujisawa has
already commenced manufacturing of the Licensed Product as to which its rights
have been terminated. Fujisawa shall continue to provide for manufacture of the
Licensed Products to the extent necessary to meet expected market demand, from
the effective date of such termination until such time as DTI is able to secure
an alternative commercial manufacturing source, as requested by DTI; provided,
that Fujisawa shall in no event be required to continue to manufacture for more
than eighteen (18) months after the effective date of such termination or in
quantities in excess of those being produced at the time of such termination. As
of the effective date of such termination, all Third Party manufacturing
contracts for manufacture of Licensed Products shall be assigned to DTI, to the
extent that Fujisawa has the right to do so, and DTI will assume any and all of
Fujisawa's obligations under any of such contracts. Except in the event of
Fujisawa's termination of this Agreement for DTI's material breach under Section
11.2, in addition, upon DTI's request, Fujisawa shall provide such technical
assistance and know-how licenses on a royalty-free basis as may reasonably be
requested to transfer such technology as is needed by DTI to commence or provide
for commercial manufacture of Licensed Product. Fujisawa shall provide such
technical assistance to DTI for a period of sixty (60) days following the
effective date of termination. Fujisawa shall only be obligated to provide such
assistance if it is promptly reimbursed for any and all out-of-pocket expenses
incurred in rendering such assistance and at a reasonable hourly rate, mutually
agreed to by the parties, for the work of the employees providing such
assistance. In the event Fujisawa is unable to assign to DTI any such
manufacturing contracts, then Fujisawa shall continue to have the Licensed
Product manufactured for a period in no event to exceed eighteen (18) months
from the effective date of termination so as to enable DTI to qualify a new
Third Party contract manufacturer. If such Third Party is qualified prior to the
end of such eighteen (18) month period, then Fujisawa's obligation to have the
Licensed Product manufactured shall cease upon the date such Third Party is so
qualified. Notwithstanding anything to the contrary contained in Section 8.1 or
8.2, during such period in which Fujisawa is continuing to have the Licensed
Product manufactured after termination of this Agreement, DTI agrees to
indemnify, defend and hold harmless, Fujisawa and its agents representatives,
consultants and employees from and against any and all Losses resulting from the
manufacture, use, handling, storage, sale or other disposition of Licensed
Products by DTI, its agents representatives, consultants or employees, and/or
the third party contract manufacturer, except to the extent such Losses result
from the negligence or wrongdoing of Fujisawa, its agents representatives,
consultants or employees (excluding any Third Party manufacturing the

                                       32

<PAGE>

Licensed Product after the effective date of such termination) in accordance
with Section 8.3. If any technology needed by DTI to commence or provide for
commercial manufacture of Licensed Product is covered by one or more patents
owned or controlled by Fujisawa, DTI shall receive a fully paid-up,
royalty-free, non-exclusive worldwide license to practice any and all such
patents for the purposes contemplated in this Section 11.7, with the right to
grant sublicenses.

         11.8     Accrued Obligations. Except where expressly provided for
otherwise in this Agreement, termination of this Agreement shall not relieve the
Parties hereto of any liability, including without limitation, any obligation to
make payments hereunder, which accrued hereunder prior to the effective date of
such termination, nor preclude any Party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice any Party's right to obtain performance of any
obligation. Upon termination, expiration or cancellation of this Agreement for
any reason and subject to Sections 5.3(b), 11.4(a), 11.4(b) 11.4(e), Fujisawa
shall not be required to make any milestone payments or royalty payments that
may be due from and after the effective date of termination. The Parties further
acknowledge and agree that notwithstanding anything to the contrary contained in
this Agreement, any DTI patent infringement action brought by Fujisawa under
Section 9.2 which is ongoing as of the time of such termination or expiration
shall be transferred to DTI, upon DTI's request. In such event, Fujisawa shall
have no responsibility with respect to the prosecution of any such action
pertaining to the infringement of the DTI Patents.

         11.9     Surviving Obligations. Surviving any termination are:

                  (a)      any cause of action or claim of Fujisawa or DTI,
accrued or to accrue, because of any breach or default by the other Party;

                  (b)      the provisions of Sections 3.9 (with respect to DTI's
rights and subject to Section 5.5), 4.4, 5.5, 5.6, 5.12, 7.1, 7.2, 7.3, 8, 9.1,
9.5, 10, 11 and 14; and

                  (c)      any accrued obligations under Section 11.8.

12.      ASSIGNMENT

         12.1     This Agreement and the rights, duties and obligations
hereunder may not be assigned by either Party without the prior written consent
of the other Party except to an Affiliate or in connection with a merger,
consolidation or sale of all or substantially all of the assets or line of
business of such Party to which this Agreement relates. This Agreement shall be
binding upon and inure to the benefit of all successors and permitted assigns of
the Parties.

13.      DISPUTE RESOLUTION

         13.1     Discussion. In the event of any dispute between the Parties
regarding their respective rights or obligations under this Agreement, each
Party agrees to discuss such matter in good faith in an effort to resolve the
dispute without resort to formal dispute resolution procedures. At any time,
either Party may call a meeting between a member of Fujisawa's Executive
Committee and the Chief Executive Officer of DTI to attempt to resolve the
dispute. Such meeting shall be held not later than ten (10) days after it is
requested in writing by either

                                       33

<PAGE>

Party in New York, New York. If such dispute cannot be resolved through such
procedures within fifteen (15) days of the date either Party requests a meeting
of the officers designated above, then either Party may request an arbitration
proceeding as provided in Section 13.2.

         13.2     Alternative Dispute Resolution. Any dispute, controversy or
claim arising out of or relating to the validity, construction, enforceability
or performance of this Agreement, including disputes relating to an alleged
breach or to termination of this Agreement and including any claim of inducement
by fraud or otherwise, but excluding (i) any dispute, regarding the validity,
enforceability, or infringement of any DTI Patent or trademark applicable to a
Licensed Product and (ii) any dispute which is expressly prohibited herein from
being resolved by this mechanism, shall be settled by binding Alternative
Dispute Resolution ("ADR") by Mediation and Arbitration in the manner described
below:

         13.3     Mediation.

                  (a)      Any such dispute, controversy or claim which would,
but for this provision, be submitted to arbitration may upon the mutual written
agreement of the Parties, before submission to arbitration, first be mediated
through non-binding mediation in accordance with the Model Procedures for the
Mediation of Business Disputes promulgated by the Center for Public Resources
("CPR") then in effect, except where those rules conflict with these provisions,
in which case these provisions control. The mediation shall be conducted in the
United States and shall be attended by a senior executive with authority to
resolve the dispute from each of the operating companies that are Parties.

                  (b)      Subject to Section 3.5(c), the mediator shall be
appointed from the list of neutrals maintained by CPR.

                  (c)      The Parties shall promptly confer in an effort to
select a mediator by mutual agreement. In the absence of such an agreement, the
mediator shall be selected from a list generated by CPR with each Party having
the right to exercise challenges for cause and two peremptory challenges within
72 hours of receiving the CPR list, subject to Section 3.5(c).

                  (d)      The mediator shall confer with the Parties to design
procedures to conclude the mediation within no more than 30 days after
initiation. Under no circumstances shall the commencement of arbitration under
Section 13.4 be delayed more than 45 days by the mediation process specified
herein.

                  (e)      Each Party agrees to toll all applicable statutes of
limitation during the mediation process and not to use the period or pendancy of
the mediation to disadvantage the other Party procedurally or otherwise. No
statements made by either side during the mediation may be used by the other
during any subsequent arbitration.

                  (f)      Each Party has the right to pursue provisional relief
from any court, such as attachment, preliminary injunction, replevin, etc., to
avoid irreparable harm, maintain the status quo, aid the arbitration or preserve
the subject matter of the arbitration, even though mediation has not been
commenced or completed.

                                       34

<PAGE>

         13.4     Arbitration. Except as provided in paragraph (c) below and
subject to Section 3.5(c), any dispute, controversy or claim arising out of or
relating to the validity, construction, enforceability or performance of this
Agreement which is not resolved by mediation, including disputes relating to
alleged breach or to termination of this Agreement, other than disputes which
are expressly prohibited under Section 13.2 from being resolved by this
mechanism, shall be settled by binding Alternative Dispute Resolution ("ADR") in
the manner described below:

                  (a)      If a Party intends to begin an ADR to resolve a
dispute, such Party shall provide written notice (the "ADR Request") to counsel
for the other Party informing such other Party of such intention and the issues
to be resolved. From the date of the ADR Request and until such time as any
matter has been finally settled by ADR, the running of the time periods
contained in Section 11.2 as to which Party must cure a breach of this Agreement
shall be suspended as to the subject matter of the dispute.

                  (b)      Within ten (10) business days after the receipt of
the ADR Request, the other Party may, by written notice to the counsel for the
Party initiating ADR, add additional issues to be resolved.

                  (c)      Notwithstanding anything to the contrary contained
herein, any dispute regarding the validity, enforceability, or infringement of
any DTI Patent or trademark applicable to a Licensed Product shall be submitted
to a court of competent jurisdiction in the country in which such patent or
trademark right exists.

         13.5     Procedure. The ADR shall be conducted pursuant to
JAMS/ENDISPUTE Streamlined Arbitration Rules & Procedures or Comprehensive
Arbitration Rules and Procedures (collectively, the "Rules"). Notwithstanding
those rules, the following provisions shall apply to the ADR hereunder.

                  (a)      Arbitrator. The arbitration shall be conducted by a
single arbitrator knowledgeable about drug development ("the Arbitrator"). The
Arbitrator shall be selected from a pool of retired independent federal judges
to be presented to the Parties by JAMS/ENDISPUTE. Neither Party shall engage in
ex parte contact with the arbitrator without first giving reasonable advance
written notice to the other Party and an opportunity to participate in such
contact.

                  (b)      Proceedings. The time periods set forth in the
JAMS/ENDISPUTE rules shall be followed, unless a Party can demonstrate to the
Arbitrator that the complexity of the issues or other reasons warrant the
extension or shortening of one or more of the time tables. In such case, the
panel may extend or shorten such time tables, but in no event shall the time
tables being extended so that the ADR proceeding extends more than 12 months
from its beginning to the Award. In regard to such time tables, that Parties (i)
acknowledge that the issues that may arise in any dispute involving this
Agreement may involve a number of complex matters and (ii) confirm their
intention that each Party will have the opportunity to conduct reasonable
discovery with respect to all material issues involved in a dispute within the
framework provided above. The Parties will exchange information as required
under current Rule 15 of the JAMS/ENDISPUTE Comprehensive Arbitration Rules and
Procedures except that (i) in addition to exchanging the names of all experts
who may be called to testify or whose report may be

                                       35

<PAGE>

introduced at the ADR hearing, the Parties shall also provide, simultaneously
with the names of all such experts, a copy of any report(s) (including all
backup) prepared by the experts, and (ii) notwithstanding anything in Rule 15 to
the contrary, and unless the Parties otherwise agree or the Arbitrator decides
upon application of a Party that additional depositions are warranted, each
Party shall be entitled to conduct one deposition of each of the opposing
Party's experts and, in addition, shall be entitled to conduct two depositions
of the opposing Party or of individuals under the control of the opposing Party.
The Arbitrator shall not award punitive damages to either Party and the Parties
shall be deemed to have waived any right to such damages. The Arbitrator shall,
in rendering its decision, apply the substantive law of the State of Delaware,
without regard to its conflict of laws provisions, except that the
interpretation of and enforcement of this Section shall be governed by the
Federal Arbitration Act. The Arbitrator shall apply the Federal Rules of
Evidence to the hearing. The proceeding shall take place in the United States.
The fees of the Arbitrators and JAMS/ENDISPUTE shall be paid by the losing
Party, which shall be designated by the Arbitrator. If the Arbitrator is unable
to designate a losing Party, it shall so state and the fees shall be split
equally between the Parties.

                  (c)      Award. The Arbitrator is empowered to award any
remedy allowed by law, including money damages, prejudgment interest and
attorneys' fee, and to grant final, complete, interim, or interlocutory relief,
including injunctive relief but excluding punitive damages.

                  (d)      Confidentiality. The ADR proceeding shall be
confidential and the Panel shall issue appropriate protective orders to
safeguard each Party's confidential Information. Except as required by law, no
Party shall make (or instruct the Panel to make) any public announcement with
respect to the proceedings or decision of the Panel without prior written
consent of each other Party. The existence of any dispute submitted to ADR, and
the award, shall be kept in confidence by the Parties and the Panel, except as
required in connection with the enforcement of such award or as otherwise
required by applicable law or upon the written request to the Arbitrator with
notice to the other Party.

14.      GENERAL

         14.1     Notices. All notices under this Agreement shall be deemed to
have been fully given when done in writing and faxed to the other Party,
deposited in the United States mail, registered or certified, or sent by express
courier (receipt confirmed) and addressed as follows:

                  To DTI:           2028 Dabney Road, Suite E-17
                                    Richmond, VA 23230-3311
                                    Fax No.: (804) 358-2451
                                    Attention: Chief Executive Officer

                  With a copy to:   Cooley Godward LLP
                                    5 Palo Alto Square
                                    3000 El Camino Real
                                    Palo Alto, CA 94306
                                    Fax No.: (650) 857-0663
                                    Attention: Barbara A. Kosacz, Esq.

                                       36

<PAGE>

                  To Fujisawa:      Fujisawa Healthcare, Inc.
                                    Parkway North Center
                                    Three Parkway North
                                    Deerfield, ILL 60015-2548
                                    Fax No.: (847) 317-7288
                                    Attention: Chief Executive Officer

                  With a copy to:   General Counsel

Either Party may change its address upon written notice to the other Party.

         14.2     Retained Rights. Subject to Sections 2.5 and 3.8, nothing in
this Agreement shall limit in any respect the right of either Party to conduct
research and development and to market products using such Party's technology
other than as herein expressly provided. Furthermore, nothing in this Agreement
shall be construed to provide any license, implied or express, under any patent
controlled by a Party, except to the extent expressly granted with respect to
Licensed Products that are the subject of continuing development and
commercialization pursuant to this Agreement.

         14.3     Consents Not Unreasonably Withheld or Delayed. Whenever
provision is made in this Agreement for either Party to secure the consent or
approval of the other, that consent or approval shall not unreasonably be
withheld or delayed, and whenever in this Agreement provision is made for one
Party to object to or disapprove a matter, such objection or disapproval shall
not unreasonably be exercised, even when not so expressly stated.

         14.4     Force Majeure. Neither Party shall lose any rights hereunder
or be liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, embargo, act of God,
failure to supply by Third Party contract manufacturer or any other similar
cause beyond the control of the defaulting Party, provided that the Party
claiming force majeure has exerted all reasonable efforts to avoid or remedy
such force majeure and has given the other Party prompt notice describing such
event, the effect thereof and the actions being taken to avoid or remedy such
force majeure; provided, however, that in no event shall a Party be required to
settle any labor dispute or disturbance.

         14.5     Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

         14.6     No Trademark Rights. Except as otherwise provided herein, no
right, express or implied, is granted by the Agreement to use in any manner any
name or any trade name or trademark of the other Party in connection with the
performance of this Agreement.

         14.7     Waiver. Except as specifically provided for herein, the waiver
from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of same or any other of such Party's rights or remedies provided in this
Agreement.

                                       37

<PAGE>

         14.8     Independent Contractors. The status of the Parties under this
Agreement shall be that of independent contractors. Neither Party shall have the
right to enter into any agreements on behalf of the other Party, nor shall it
represent to any person that it has any such right or authority. Nothing in this
Agreement shall be construed as establishing a partnership, agency or joint
venture relationship between the Parties.

         14.9     Entire Agreement. This Agreement and the Exhibits attached
hereto embodies the entire understanding between the Parties relating to the
subject matter hereof and supersedes all prior understandings and agreements,
whether written or oral. None of the terms of this Agreement can be amended or
waived except by an instrument in writing executed by authorized representatives
of each Party.

         14.10    Governing Law. This Agreement shall be governed by the laws of
the State of Delaware, without regard to conflict of laws principles.

         14.11    Severability. Any of the provisions of this Agreement which
are determined to be invalid or unenforceable in any jurisdiction shall be
ineffective to the extent of such invalidity or unenforceability in such
jurisdiction, without rendering invalid or unenforceable the remaining
provisions hereof or affecting the validity or enforceability of any of the
terms of this Agreement in any other jurisdiction.

         14.12    Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which taken
together shall constitute one and the same instrument.

         IN WITNESS WHEREOF, the Parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

Discovery Therapeutics, Inc.                    Fujisawa Healthcare, Inc.

By:    /s/ Donald A. McAfee                     By:    /s/ Noboru Maeda
       -------------------------------------           -------------------------
Name:  Donald A. McAfee                         Name:  Noboru Maeda
Title: President and Chief Executive Officer    Title: Chief Executive Officer

                                       38

<PAGE>

                                    EXHIBIT A

                                    COMPOUND*

--------------------------------------------------------------------------------
 * Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.
--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT B

                                DEVELOPMENT PLAN

                                        *

--------------------------------------------------------------------------------
*Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.
--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT C

                              DEVELOPMENT EXPENSES

SUMMARY OF DTI EXPENDITURES JANUARY - JULY, 1999

<TABLE>
<S>                                                             <C>
Drug Substance Manufacturing (*)                                *

Drug Substance Characterization (*)                             *

Drug Product Manufacturing (PDC)                                *

Regulatory (Quintiles)                                          *

Plasma Assay (PPD)                                              *

Toxicology (Covance)                                            *

DTI Internal Effort 1Q99                                        *

DTI Internal Effort 2Q99                                        *

DTI Internal Effort July                                        *

Grand Total Expenditures Due in accordance with Section 5.2
of the Development and License Agreement                        *
</TABLE>

--------------------------------------------------------------------------------
 * Certain information on this page has been omitted and filed separately with
 the Securities and Exchange Commission. Confidential treatment has been
 requested with respect to the omitted portions.
--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT D

                             [Intentionally omitted]

<PAGE>

                                    EXHIBIT E

                              PHASE I TRIAL BUDGET

<TABLE>
<CAPTION>
          Activity                         Vendor       Cost
---------------------------               --------    --------
<S>                                       <C>         <C>
Clinical Site Expenses                        *           *
Data Management                               *           *
Randomization                                 *           *
Medical Monitor                               *           *
Plasma Assay                                  *           *
Bulk Drug Stability                           *           *
Drug Product Stability                        *           *
Drug Product Storage                          *           *
Regulatory                                    *           *
DTI Internal FTE and Misc.                                *
DTI Travel to Clinical Site                   *           *

Total                                                     *

Estimated Amount due from Fujisawa per
Section 5.2 of Development and License
Agreement                                                 *

Assumptions:
% of total supporting Licensed Products
studies                                       *
</TABLE>

--------------------------------------------------------------------------------
 * Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

<PAGE>

                                    EXHIBIT F

U.S. PATENT NO:                     5,310,731
                               Issued May 10, 1994

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]